185 results on '"Trochu JN"'
Search Results
2. Case-based session: unusual and multitrouble cases: Saturday 6 December 2014, 08: 30–10: 0Location: Agora
- Author
-
Piriou, N, Sassier, J, Pallardy, A, Valette, F, Serfaty, JM, and Trochu, JN
- Published
- 2014
3. The added value of contrast-enhanced cardiac magnetic resonance to predict positive genetic testing in clinically suspected Lamin A/C cardiomyopathy
- Author
-
Delhommeau, P, primary, Marteau, L, additional, Kyndt, F, additional, Constant Dit Beaufils, AL, additional, Warin-Fresse, K, additional, Serfaty, JM, additional, Rousseau, O, additional, Karakachoff, M, additional, Conan, E, additional, Clero, S, additional, Le Tourneau, T, additional, Thollet, A, additional, Trochu, JN, additional, Probst, V, additional, and Piriou, N, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Poster session Thursday 12 December - AM: 12/12/2013, 08: 30–12: 30Location: Poster area
- Author
-
Le Tourneau, T, Kyndt, F, Lecointe, S, Duval, D, Rimbert, A, Merot, J, Trochu, JN, Probst, V, Le Marec, H, and Schott, JJ
- Published
- 2013
5. Poster session Friday 7 December - PM: Effect of systemic illnesses on the heart
- Author
-
Le Tourneau, T, Probst, V, Kyndt, F, Duval, D, Trochu, JN, Bernstein, J, Hagege, AA, Levine, R, Le Marec, H, and Schott, JJ
- Published
- 2012
6. Oral Abstract SessionNew insights into primary mitral regurgitation: Valvular heart disease associated with systemic conditions and others
- Author
-
Le Tourneau, T, Deswartes, G, Richardson, M, Foucher, C, Polge, AS, Fayad, G, Vincentelli, A, Lamblin, N, Trochu, JN, and Bauters, C
- Published
- 2012
7. Poster session: Dobutamine stress echo
- Author
-
Le Tourneau, T, Sportouch, C, Foucher, C, Delasalle, B, Rosso, J, Neuder, Y, Trochu, JN, Roncalli, J, Lemarchand, P, and Manrique, A
- Published
- 2012
8. Transthyretin amyloid polyneuropathy in France: a cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019)
- Author
-
Adams, D., Cintas, P., Solé, G., Tard, C., Labeyrie, C., Echaniz-Laguna, A., Cauquil, C., Pereon, Y., Magy, L., Juntas Morales, R., Antoine, JC., Lagrange, E., Petiot, P., Mallaret, M., Francou, B., Guiochon-Mantel, A., Coste, A., Demarcq, O., Geffroy, C., Famelart, V., Rudant, J., Bartoli, M., Donal, E., Lairez, O., Eicher, JC., Kharoubi, M., Oghina, S., Trochu, JN., Inamo, J., Habib, G., Roubille, F., Hagège, A., Morio, F., Cariou, E., Adda, J., Slama, MS., Charron, P., Algalarrondo, V., Damy, T., and Attarian, S.
- Abstract
Objective: We aimed to describe characteristics of patients with ATTR variant polyneuropathy (ATTRv-PN) and ATTRv-mixed and assess the real-world use and safety profile of tafamidis meglumine 20 mg.
- Published
- 2024
- Full Text
- View/download PDF
9. The underestimated burden of mitral regurgitation: morbidity, mortality, and risk factors
- Author
-
Mitchell SA, Trochu JN, Gustafsson F, Mitrovic V, Dillon R., ALFIERI , OTTAVIO, Mitchell, Sa, Alfieri, Ottavio, Trochu, Jn, Gustafsson, F, Mitrovic, V, and Dillon, R.
- Published
- 2014
10. Eplerenone in patients with systolic heart failure and mild symptoms
- Author
-
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Drexler H, McMurray J, Remme WJ, Cornel JH, Hildebrandt P, Hradec J, Mareev V, Reddy KS, Sindone A, Martinez F, Alonso Garcia A, Wilhelmsen L, Dargie HJ, Tavazzi L, Pocock S, Leizorovic A, Collier T, Nul DR, Serra JL, Thierer JM, Cross DB, Sindone AP, Singh BB, Boreux JL, Charlier FP, Dendale P, De Keulenaer G, Marchandise B, Marechal P, Marenne F, Mieghem WV, Van Dorpe AC, Vanhaecke J, Arnold JM, Dion D, Huynh T, Kouz SM, Lepage S, McKelvie RS, O'Meara E, Proulx G, Sauve C, Aschermann M, Brecka D, Filipovsky J, Groch L, Jerabek O, Jokl I, Linkova H, Motovska Z, Munz J, Penicka M, Rucka D, Mid JS, Spacek R, Spinar J, Stipal R, Vojacek J, Attali P, Bonneau A, Bousser JP, Dutoit L, Funck F, Galinier MP, Gibelin P, Hautefeuille BD, Hittinger L, Jobic Y, Jourdain P, Komajda M, Maupas E, Olive T, Philias A, Roul G, Rouleau F, Trochu JN, Boehm M, Bruch L, Engelhardt H, Erbs S, Foerster A, Franz N, Hambrecht R, Heuer H, Krueger U, Landmesser U, Leischik R, Mitrovic V, Moehlenkamp S, Monti J, Mueller Ehmsen J, Oezcelik C, Philipp S, Pieske B, Roehnisch JU, Schunkert H, Schwinger R, Wachter R, Willenbrock R, Winkelmann BR, Winkler R, Wollert KC, Adamopoulos S, Kalikazaros I, Karavidas A, Karvounis H, Kremastinos D, Manolis AJ, Nanas I, Sotirellos K, Vasiliadis K, Zaboulis C, Lee S, Yu CM, Czibok C, Édes I, Forster T, Preda I, Simon K, Takacs J, Zámolyi K, Bhagavatula KS, Chockalingam K, Desai N, Iyengar SS, Jayadev SM, Mullasari AS, Sathe SP, Sinha N, Vadagenalli PS, Wander GS, McDonald KM, Nash P, Vaughan CJ, Agostoni P, Ambrosio GB, Bittolo Bon G, Boffa G, Cacciavillani L, Capucci A, Chiariello M, Cirrincione V, Gensini GF, Masini F, Modena MG, Monte I, Rosano GM, Senni M, Sinagra G, Tamburino C, Terrosu P, Villani GQ, Volterrani M, Chae SC, Ha CW, Ha JW, Shin JH, Bayram Llamas E, Calvillo JC, Cruz Diaz A, Delgado Leal L, Estrada Gomez MM, Kosturakis D, Petersen Aranguren F, Velasco Sanchez RG, Daniëls MC, Dirkali A, Dunselman PH, de Kluiver EP, Kragten JA, Lok DJ, Maas AH, Michels HR, Nicastia DM, Stoel I, de Swart JB, Thijssen HJ, Van Kempen LH, Voors AA, Willems FF, Dluzniewski M, Gaciong Z, Kawecka Jaszcz K, Jozwa R, Korewicki J, Krzeminska Pakula M, Kurowski M, Ogorek M, Pempera M, Rynkiewicz A, Ujda M, Wierzchowiecki M, Abreu Á, Andrade A, Carrageta M, Fonseca C, Franco F, Gil VM, Lousada N, Mendonca C, Moreira I, Padua FP, Providência L, Cardoso JC, Trabulo M, Aroutyunov GP, Gindin K, Karpov YB, Kostenko VA, Nikitin YP, Obraztsova GI, Shilkina NP, Shlyakhto EV, Skvortsov A, Ding ZP, Yeo DP, Ambrovicova V, Gaspar L, Goncalvesova E, Kycina P, Litvinova J, Mikes Z, Murin J, Poliacik P, Uhliar R, Lloyd EA, Marx D, Naidoo DP, Prozesky HW, Sliwa Hahnle K, Theron H, Anguita M, De Teresa E, Galve E, Juanatey JR, Orbe PM, Vida M, Ahremark U, Andersson B, Axelsson U, Berglund S, Boman K, Dahlstrom U, Fu M, Holm Orndahl L, Johansson A, Lindgren M, Nemeczek C, Prantare H, Roussine V, Stehn G, Stenberg A, Vasko P, Bazylevych A, Dyadyk OI, Dzyak GV, Girina OM, Ignatenko GA, Kononenko LG, Kubyshkin VF, Kuryata OV, Parkhomenko AN, Perepelytsya MV, Pertseva TO, Popik GS, Rishko MV, Sakharchuk II, Tseluyko VI, Tykhonova SA, Vizir V, Voronkov LG, Al Khaja N, Almahmeed WA, Bazargani N, Adgey AA, Al Mohammad A, Banerjee P, Barlow M, Bridges AB, Brooks N, Connolly EC, Denvir MA, Egdell RM, Kardos A, Keeling PJ, Khokhar AA, Senior R, Williams SG, Anand IS, Anderson JL, Berk MR, Bertolet BD, Bisognano JD, Blonder RD, Breburda CS, Canaday DB, Capodilupo RC, Choiunard MD, Colucci WS, Dahiya RJ, Dunlap SH, Essandoh LK, Flores AR, Henderson DA, Herzog WR Jr, Katz RJ, Kosinski EJ, Labin IN, Lally FL, Lash JA, McGrew FA 3rd, Mohiuddin SM, Moraes D, Murali SC, Nallasivan M, Philbin E, Prabhu S, Primack DS, Ramani R, Rawitscher D, Sangrigoli R, Schamalfuss CM, Stoletniy L, Strong MH, Thadani U, Treasure CB 2nd, Vicari RM, Vogel CD, Wlsh MN, Wencker D, Wilson SA, Winkel E, Wiseman AH, Zoiopoulos LY, Mancebo JR, Mendoza I, Waich S.T., PERRONE FILARDI, PASQUALE, Zannad, F, Mcmurray, Jj, Krum, H, van Veldhuisen, Dj, Swedberg, K, Shi, H, Vincent, J, Pocock, Sj, Pitt, B, Drexler, H, Mcmurray, J, Remme, Wj, Cornel, Jh, Hildebrandt, P, Hradec, J, Mareev, V, Reddy, K, Sindone, A, Martinez, F, Alonso Garcia, A, Wilhelmsen, L, Dargie, Hj, Tavazzi, L, Pocock, S, Leizorovic, A, Collier, T, Nul, Dr, Serra, Jl, Thierer, Jm, Cross, Db, Sindone, Ap, Singh, Bb, Boreux, Jl, Charlier, Fp, Dendale, P, De Keulenaer, G, Marchandise, B, Marechal, P, Marenne, F, Mieghem, Wv, Van Dorpe, Ac, Vanhaecke, J, Arnold, Jm, Dion, D, Huynh, T, Kouz, Sm, Lepage, S, Mckelvie, R, O'Meara, E, Proulx, G, Sauve, C, Aschermann, M, Brecka, D, Filipovsky, J, Groch, L, Jerabek, O, Jokl, I, Linkova, H, Motovska, Z, Munz, J, Penicka, M, Rucka, D, Mid, J, Spacek, R, Spinar, J, Stipal, R, Vojacek, J, Attali, P, Bonneau, A, Bousser, Jp, Dutoit, L, Funck, F, Galinier, Mp, Gibelin, P, Hautefeuille, Bd, Hittinger, L, Jobic, Y, Jourdain, P, Komajda, M, Maupas, E, Olive, T, Philias, A, Roul, G, Rouleau, F, Trochu, Jn, Boehm, M, Bruch, L, Engelhardt, H, Erbs, S, Foerster, A, Franz, N, Hambrecht, R, Heuer, H, Krueger, U, Landmesser, U, Leischik, R, Mitrovic, V, Moehlenkamp, S, Monti, J, Mueller Ehmsen, J, Oezcelik, C, Philipp, S, Pieske, B, Roehnisch, Ju, Schunkert, H, Schwinger, R, Wachter, R, Willenbrock, R, Winkelmann, Br, Winkler, R, Wollert, Kc, Adamopoulos, S, Kalikazaros, I, Karavidas, A, Karvounis, H, Kremastinos, D, Manolis, Aj, Nanas, I, Sotirellos, K, Vasiliadis, K, Zaboulis, C, Lee, S, Yu, Cm, Czibok, C, Édes, I, Forster, T, Preda, I, Simon, K, Takacs, J, Zámolyi, K, Bhagavatula, K, Chockalingam, K, Desai, N, Iyengar, S, Jayadev, Sm, Mullasari, A, Sathe, Sp, Sinha, N, Vadagenalli, P, Wander, G, Mcdonald, Km, Nash, P, Vaughan, Cj, Agostoni, P, Ambrosio, Gb, Bittolo Bon, G, Boffa, G, Cacciavillani, L, Capucci, A, Chiariello, M, Cirrincione, V, Gensini, Gf, Masini, F, Modena, Mg, Monte, I, PERRONE FILARDI, Pasquale, Rosano, Gm, Senni, M, Sinagra, G, Tamburino, C, Terrosu, P, Villani, Gq, Volterrani, M, Chae, Sc, Ha, Cw, Ha, Jw, Shin, Jh, Bayram Llamas, E, Calvillo, Jc, Cruz Diaz, A, Delgado Leal, L, Estrada Gomez, Mm, Kosturakis, D, Petersen Aranguren, F, Velasco Sanchez, Rg, Daniëls, Mc, Dirkali, A, Dunselman, Ph, de Kluiver, Ep, Kragten, Ja, Lok, Dj, Maas, Ah, Michels, Hr, Nicastia, Dm, Stoel, I, de Swart, Jb, Thijssen, Hj, Van Kempen, Lh, Voors, Aa, Willems, Ff, Dluzniewski, M, Gaciong, Z, Kawecka Jaszcz, K, Jozwa, R, Korewicki, J, Krzeminska Pakula, M, Kurowski, M, Ogorek, M, Pempera, M, Rynkiewicz, A, Ujda, M, Wierzchowiecki, M, Abreu, Á, Andrade, A, Carrageta, M, Fonseca, C, Franco, F, Gil, Vm, Lousada, N, Mendonca, C, Moreira, I, Padua, Fp, Providência, L, Cardoso, Jc, Trabulo, M, Aroutyunov, Gp, Gindin, K, Karpov, Yb, Kostenko, Va, Nikitin, Yp, Obraztsova, Gi, Shilkina, Np, Shlyakhto, Ev, Skvortsov, A, Ding, Zp, Yeo, Dp, Ambrovicova, V, Gaspar, L, Goncalvesova, E, Kycina, P, Litvinova, J, Mikes, Z, Murin, J, Poliacik, P, Uhliar, R, Lloyd, Ea, Marx, D, Naidoo, Dp, Prozesky, Hw, Sliwa Hahnle, K, Theron, H, Anguita, M, De Teresa, E, Galve, E, Juanatey, Jr, Orbe, Pm, Vida, M, Ahremark, U, Andersson, B, Axelsson, U, Berglund, S, Boman, K, Dahlstrom, U, Fu, M, Holm Orndahl, L, Johansson, A, Lindgren, M, Nemeczek, C, Prantare, H, Roussine, V, Stehn, G, Stenberg, A, Vasko, P, Bazylevych, A, Dyadyk, Oi, Dzyak, Gv, Girina, Om, Ignatenko, Ga, Kononenko, Lg, Kubyshkin, Vf, Kuryata, Ov, Parkhomenko, An, Perepelytsya, Mv, Pertseva, To, Popik, G, Rishko, Mv, Sakharchuk, Ii, Tseluyko, Vi, Tykhonova, Sa, Vizir, V, Voronkov, Lg, Al Khaja, N, Almahmeed, Wa, Bazargani, N, Adgey, Aa, Al Mohammad, A, Banerjee, P, Barlow, M, Bridges, Ab, Brooks, N, Connolly, Ec, Denvir, Ma, Egdell, Rm, Kardos, A, Keeling, Pj, Khokhar, Aa, Senior, R, Williams, Sg, Anand, I, Anderson, Jl, Berk, Mr, Bertolet, Bd, Bisognano, Jd, Blonder, Rd, Breburda, C, Canaday, Db, Capodilupo, Rc, Choiunard, Md, Colucci, W, Dahiya, Rj, Dunlap, Sh, Essandoh, Lk, Flores, Ar, Henderson, Da, Herzog WR, Jr, Katz, Rj, Kosinski, Ej, Labin, In, Lally, Fl, Lash, Ja, McGrew FA, 3rd, Mohiuddin, Sm, Moraes, D, Murali, Sc, Nallasivan, M, Philbin, E, Prabhu, S, Primack, D, Ramani, R, Rawitscher, D, Sangrigoli, R, Schamalfuss, Cm, Stoletniy, L, Strong, Mh, Thadani, U, Treasure CB, 2nd, Vicari, Rm, Vogel, Cd, Wlsh, Mn, Wencker, D, Wilson, Sa, Winkel, E, Wiseman, Ah, Zoiopoulos, Ly, Mancebo, Jr, Mendoza, I, and Waich, S. T.
- Published
- 2011
11. HIT Moderated Poster session: imaging in everyday practiceP143Relationship of FDG-PET and pressure-strain loops as novel measures of regional myocardial workload in LBBB-like dyssynchronyP144Cardiotoxicity of anti-vascular endothelial growth factor therapies: results of a pilot studyP145A new animal model of rapid pacing-induced dilated cardiomyopathy and LBBBP146Three-dimensional echocardiography assessment of the systolic variation of effective regurgitant orifice area in patients with functional tricuspid regurgitation: implications for quantificationP147Clinical prognostic value of myocardial mechanics using speckle-tracking echocardiography in patients post primary coronary intervention for acute ST- segment elevation myocardial infarctionP148Relationship between left atrial volumes and emptying fractions and parameters of infarct size and left ventricular filling pressures in survivors of st elevation myocardial infarctionP149Left atrial dysfunction assessed by two dimensional speckle tracking echocardiography in patients with impaired left ventricular ejection fraction and sleep-disordered breathingP150Left atrial morphological and functional remodeling early after ST elevation myocardial infarction insights from threedimensional echocardiographyP151Circumferential strain and strain rate at early stages of dobutamine speckle tracking imaging: are they enough to detect ischemia in patients with coronary artery disease?P152Pulmonary hypertension in hypertrophic cardiomyopathy: a rest and exercise echocardiography study
- Author
-
Duchenne, J, primary, Popara-Voica, AM, primary, Aruta, P, primary, Teo, HK, primary, Onciul, S, primary, Miskowiec, D, primary, Rumbinaite, E, primary, Abellard, JA, primary, Turco, A, additional, Claus, P, additional, Vunckx, K, additional, Pagourelias, E, additional, Rega, F, additional, Gheysens, O, additional, Voigt, JU, additional, Croitoru, A, additional, Alexandru, D, additional, Geavlete, D O, additional, Popescu, B A, additional, Ginghina, C, additional, Jurcut, R, additional, Haemers, P, additional, Van Puyvelde, J, additional, Muraru, D, additional, Janei, C, additional, Haertel Miglioranza, M, additional, Cavalli, G, additional, Romeo, G, additional, Peluso, D, additional, Cucchini, U, additional, Iliceto, S, additional, Badano, L, additional, Kui, SL, additional, Chai, SC, additional, Leong, KT, additional, Tong, KL, additional, Miglioranza, MH, additional, Dorobantu, M, additional, Badano, LP, additional, Kupczynska, K, additional, Uznanska-Loch, B, additional, Kasprzak, JD, additional, Kurpesa, M, additional, Lipiec, P, additional, Vaskelyte, JJ, additional, Lapinskas, T, additional, Karuzas, A, additional, Zvirblyte, R, additional, Viezelis, M, additional, Jonauskiene, I, additional, Gustiene, O, additional, Slapikas, R, additional, Trochu, JN, additional, Gueffet, JP, additional, Cueff, C, additional, De Groote, P, additional, Bauters, C, additional, Millaire, A, additional, Polge, AS, additional, and Le Tourneau, T, additional
- Published
- 2015
- Full Text
- View/download PDF
12. Moderated Posters session: complementary role of imaging techniquesP184Submillisievert computed tomography with model-based iterative reconstruction before pulmonary veins radiofrequency catheter ablation of atrial fibrillation: impact on radiation exposure and outcomeP185Calcium score and CT coronary angiography can be a low cost strategy for the investigation of patients with chest pain with low and intermediate predicted riskP186Impact of imaging modality on the heritability estimates of aortic root geometry: a classical twin studyP187Diagnosis of cardiac allograft vasculopathy with cardiac CT. Relation between clinical variables and mid-term prognosisP188Stress-only normal SPECT myocardial perfusion imaging: is it enough?P189Global longitudinal strain and its relation to cardiac autonomic denervation as assessed by 123-mIBG scintigraphy: insights from the BETTER-HF trialP190FDG-PET imaging in suspected inflammatory cardiomyopathies : comparison with the classical pattern of cardiac sarcoidosis and impact on diagnosisP191CT coronary angiography can be an effective alternative to imaging stress tests in patients with high pre-test probability of CADP192Outcomes at long term follow up of subclinical and mild coronary artery disease diagnosed with MDCT in Mediterranean EuropeP193Cardiac ct peri-device flow after percutaneous left atrial appendage closure using the amplatzer cardiac plug device
- Author
-
Pontone, G, primary, Demir, OM, primary, Celeng, C, primary, Llao-Ferrando, JI, primary, Kitsiou, A N, primary, Portugal, G, primary, Becoulet, L, primary, Marcos-Alberca Moreno, P, primary, Iriart, X, primary, Andreini, D, additional, Annoni, A, additional, Petulla, M, additional, Russo, E, additional, Innocenti, E, additional, Guglielmo, M, additional, Mushtaq, S, additional, Tondo, C, additional, Pepi, M, additional, Bashir, A, additional, Marshall, K, additional, Douglas, M, additional, Wasan, B, additional, Plein, S, additional, Alfakih, K, additional, Kolossvary, M, additional, Kovacs, A, additional, Szilveszter, B, additional, Molnar, A, additional, Horvath, T, additional, Jermendy, AL, additional, Tarnoki, AD, additional, Merkely, B, additional, Maurovich-Horvat, P, additional, Castro, JC, additional, Vilades-Medel, D, additional, Mirabet, S, additional, Pons-Llado, G, additional, Roig, E, additional, Leta, R, additional, Papanikolaou, S, additional, Griroriou, K, additional, Antonopoulos, M, additional, Mpouki, M, additional, Moustakas, G, additional, Giougi, A, additional, Giannakopoulos, V, additional, Gionakis, G, additional, Balomenos, A, additional, Abreu, A, additional, Rio, P, additional, Santos, V, additional, Martins Oliveira, M, additional, Silva Cunha, P, additional, Mota Carmo, M, additional, Branco, L M, additional, Morais, L, additional, Cruz Ferreira, R, additional, Guijarro, D, additional, Pallardy, A, additional, Mathieu, C, additional, Valette, F, additional, Gueffet, JP, additional, Serfaty, JM, additional, Kraeber-Bodere, F, additional, Trochu, JN, additional, Piriou, N, additional, Perez-Isla, L, additional, Palacios, J, additional, Gomez De Diego, JJ, additional, Islas, F, additional, De Agustin, JA, additional, Luaces, M, additional, Arrazola, J, additional, Garcia-Fernandez, MA, additional, Macaya, C, additional, Selmi, W, additional, Jalal, Z, additional, and Thambo, JB, additional
- Published
- 2015
- Full Text
- View/download PDF
13. Shoshin béri-béri: une observation avec étude échocardiographique et hémodynamique
- Author
-
Bergez, C, primary, Trochu, JN, additional, Granier, H, additional, Morand, C, additional, Lemarec, C, additional, Martin, J, additional, and Abgrall, J, additional
- Published
- 1993
- Full Text
- View/download PDF
14. Diagnostic value and safety of early adenosine TL 201-SPECT to predict severity of CAD in patients with unstable angina
- Author
-
R. Grossetête, J. Helias, Trochu Jn, Godin Jf, D. Crochet, and C. Cadiou
- Subjects
medicine.medical_specialty ,Unstable angina ,business.industry ,CAD ,medicine.disease ,Adenosine ,Tl 201 spect ,Internal medicine ,medicine ,Cardiology ,Radiology, Nuclear Medicine and imaging ,In patient ,Cardiology and Cardiovascular Medicine ,business ,Value (mathematics) ,medicine.drug - Published
- 1995
15. Safety and diagnostic value of early adenosine-Thallium-SPECT for patients with acute coronary insufficiency
- Author
-
R. Grossetête, J. Helias, D. Crochet, C. Cadiou, Godin Jf, and Trochu Jn
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Cardiology ,medicine ,Radiology, Nuclear Medicine and imaging ,Thallium spect ,Acute coronary insufficiency ,Cardiology and Cardiovascular Medicine ,business ,Value (mathematics) ,Adenosine ,medicine.drug - Published
- 1995
16. Churg-Strauss syndrome revealed by granulomatous acute pericarditis: two case reports and a review of the literature.
- Author
-
Agard C, Rendu E, Leguern V, Ponge T, Masseau A, Barrier JH, Trochu JN, Hamidou MA, and Guillevin L
- Abstract
BACKGROUND: Churg-Strauss syndrome (CSS) is a necrotizing systemic vasculitis with extravascular granulomas and eosinophilic infiltrates of small vessels. CSS is usually revealed by nonspecific signs of necrotizing vasculitis in a context of late-onset asthma and blood eosinophilia. It is considered a systemic vasculitis with the highest prevalence of cardiac involvement and can lead to rapid-onset heart failure due to specific cardiomyopathy. Pericardial effusion may also occur during CSS and is usually well tolerated. OBJECTIVE: The objective of these case reports was to indicate that CSS may present as tamponade, with or without other visceral involvement. METHODS: Among CSS patients treated during the past 10 years at 2 French university hospitals, we have identified and described 2 cases revealed by tamponade with pericardial biopsy-proven granulomatous vasculitis. We have also reviewed the international medical literature in PubMed on cardiac involvement in CSS. RESULTS: The first case report describes a 66-year-old man who had an isolated cardiac tamponade with both inflammatory syndrome and eosinophilia. Long-term remission was obtained with corticosteroids. The second case report describes a 46-year-old woman whose CSS presented with tamponade and associated central nervous system and myocardial involvement. Remission was obtained with corticosteroids and cyclophosphamide. In both cases, CSS was assessed by histological analysis of a pericardial sample. CONCLUSIONS: CSS may present as isolated cardiac tamponade. Whereas pericarditis with myocardial injury warrants immunosuppressive therapy, isolated pericarditis without other visceral involvement of poor prognosis only requires corticosteroid therapy. Copyright © 2007 by Elsevier Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
17. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy.
- Author
-
Kyndt F, Gueffet JP, Probst V, Jaafar P, Legendre A, Le Bouffant F, Toquet C, Roy E, McGregor L, Lynch SA, Newbury-Ecob R, Tran V, Young I, Trochu JN, Le Marec H, and Schott JJ
- Published
- 2007
18. HIT Moderated Poster session: imaging in everyday practice
- Author
-
Duchenne, J, Turco, A, Claus, P, Vunckx, K, Pagourelias, E, Rega, F, Gheysens, O, Voigt, JU, Popara-Voica, AM, Croitoru, A, Alexandru, D, Geavlete, D O, Popescu, B A, Ginghina, C, Jurcut, R, Duchenne, J, Claus, P, Turco, A, Vunckx, K, Pagourelias, E, Haemers, P, Van Puyvelde, J, Gheysens, O, Rega, F, Voigt, JU, Aruta, P, Muraru, D, Janei, C, Haertel Miglioranza, M, Cavalli, G, Romeo, G, Peluso, D, Cucchini, U, Iliceto, S, Badano, L, Teo, HK, Kui, SL, Chai, SC, Leong, KT, Tong, KL, Onciul, S, Muraru, D, Miglioranza, MH, Cucchini, U, Dorobantu, M, Iliceto, S, Badano, LP, Miskowiec, D, Kupczynska, K, Uznanska-Loch, B, Kasprzak, JD, Kurpesa, M, Lipiec, P, Onciul, S, Muraru, D, Miglioranza, MH, Cucchini, U, Dorobantu, M, Iliceto, S, Badano, LP, Rumbinaite, E, Vaskelyte, JJ, Lapinskas, T, Karuzas, A, Zvirblyte, R, Viezelis, M, Jonauskiene, I, Gustiene, O, Slapikas, R, Abellard, JA, Trochu, JN, Gueffet, JP, Cueff, C, De Groote, P, Bauters, C, Millaire, A, Polge, AS, and Le Tourneau, T
- Abstract
Purpose: To investigate the relationship between two measures of regional myocardial workload (RMW): regional myocardial glucose metabolism, assessed by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and regional LV pressure-strain loop area. Both were evaluated in a chronic rapid pacing animal model of dilated cardiomyopathy (DCM) and LBBB-like mechanical dyssynchrony. Methods: Nine sheep were subjected to rapid RV pacing (180 bpm), developing LV dilatation and asymetric remodelling, with LBBB-like ventricular activation. After 8 weeks all animals underwent two FDG-PET scans: one under normal LV conduction (AAI pacing), another under LBBB-like activation (DDD pacing). Potential inhomogeneities in RMW represented by FDG-uptake, were then evaluated. Before the last PET scan, all animals were subjected to invasive pressure-volume and simultaneous echocardiographic circumferential strain (CS) analysis of the mid-ventricular segments. Segmental pressure-CS-loop area was then recorded as alternative measure of RMW and compared to PET results. Results: DDD and AAI pacing led to different, but reproducible patterns of inhomogeneous RMW distribution (Figure) with a significant decreased septal-to-lateral wall ratio of RMW in DDD mode compared to AAI, both in the FDG-uptake (0.87 ± 0.09 vs 1.05 ± 0.15, resp., p=0.005) and pressure-strain loops area (0.22 ± 0.18 vs 0.94 ± 0.23, resp., p=0.0001). A significant correlation was found between both measures (r=0.584, p=0.018). Conclusions: Our study indicates that RMW can be measured with both regional FDG-uptake and the area of regional pressure-strain loops. The influence of motion and partial volume on the reconstructed FDG-uptake in the asymmetrically remodelled hearts is currently being investigated.
- Published
- 2015
- Full Text
- View/download PDF
19. Moderated Posters session: complementary role of imaging techniques
- Author
-
Pontone, G, Andreini, D, Annoni, A, Petulla, M, Russo, E, Innocenti, E, Guglielmo, M, Mushtaq, S, Tondo, C, Pepi, M, Demir, OM, Bashir, A, Marshall, K, Douglas, M, Wasan, B, Plein, S, Alfakih, K, Celeng, C, Kolossvary, M, Kovacs, A, Szilveszter, B, Molnar, A, Horvath, T, Jermendy, AL, Tarnoki, AD, Merkely, B, Maurovich-Horvat, P, Llao-Ferrando, JI, Castro, JC, Vilades-Medel, D, Mirabet, S, Pons-Llado, G, Roig, E, Leta, R, Kitsiou, A N, Papanikolaou, S, Griroriou, K, Antonopoulos, M, Mpouki, M, Moustakas, G, Giougi, A, Giannakopoulos, V, Gionakis, G, Balomenos, A, Portugal, G, Abreu, A, Rio, P, Santos, V, Martins Oliveira, M, Silva Cunha, P, Mota Carmo, M, Branco, L M, Morais, L, Cruz Ferreira, R, Becoulet, L, Guijarro, D, Pallardy, A, Mathieu, C, Valette, F, Gueffet, JP, Serfaty, JM, Kraeber-Bodere, F, Trochu, JN, Piriou, N, Demir, OM, Bashir, A, Marshall, K, Wasan, B, Plein, S, Alfakih, K, Marcos-Alberca Moreno, P, Perez-Isla, L, Palacios, J, Gomez De Diego, JJ, Islas, F, De Agustin, JA, Luaces, M, Arrazola, J, Garcia-Fernandez, MA, Macaya, C, Iriart, X, Selmi, W, Jalal, Z, and Thambo, JB
- Abstract
Background: The outcome of radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) has improved thanks to left atrium (LA) anatomy reconstruction by computed tomography with adaptive statistical iterative reconstruction algorithm (CT-ASIR) before the procedure. However, CT-ASIR strategy is associated to an increase of cumulative effective radiation dose (ED) in these patients. Recently, a model-based iterative reconstruction algorithm (MBIR, GE Healthcare, Waukesha,Wisconsin) has been developed (CT-MBIR) for image noise reduction reducing the ED close to chest X-ray exposure. The aim of this study is to compare the CT and RFCA characteristics, AF recurrence after procedure and radiation exposure between RFCA guided by image integration with CT-ASIR versus CT-MBIR Methods and Materials: One-hundred twenty consecutive patients with drug-refractory paroxysmal or persistent AF were addressed to CT-ASIR (Group 1; N: 60; mean age 60.3 ± 10.1 yo; male: 46) or CT-MBIR protocol (Group 2; N: 60; mean age 59.7 ± 11.3 yo; male:45) for evaluation of LA before RFCA. All patients were subsequently treated by image integration-supported RFCA. Image noise, signal to noise ratio (SNR), contrast to noise ratio (CNR), RFCA procedural characteristics, rate of AF recurrence and CT radiation exposure were measured and compared between the two groups. Results: The two groups were homogeneous in terms of demographic characteristics, cardiovascular risk factors, prevalence of persistent AF, medical therapy and echocardiographic characteristics. The mean follow-up was similar (578 ± 284 vs. 591 ± 278 days, respectively, p:ns). Group 2 showed a higher signal to noise ratio (25.9 ± 7.1 vs. 13.8 ± 5.1) and contrast to noise ratio (22.7 ± 6.5 vs. and 14.08 ± 4.1) of left atrium as compared to Group 1 (p<0.001). No differences were found in terms of RFCA parameter [procedural duration (130.9 ± 130.6. vs. 143.8 ± 80.4 min); fluoroscopy time (27.9 ± 14.1.0 vs. 32.0 ± 16.4 min); pulmonary veins isolated (3.8 ± 0.4 vs. 3.9 ± 0.4)] and the rate of AF recurrence (31% vs. 29%) between Group 2 vs Group 1. Group 2 showed a 94% reduction of ED as compared to Group 1 (0.4 ± 0.04 mSv vs 6.4 ± 1.8 mSv, p<0.01). Conclusions: CT-MBIR allows accurate non-invasive reconstruction of LA anatomy in AF patients undergoing to RFCA with a submillisievert effective radiation and comparable success rate of RFCA with CT-ASIR technique.
- Published
- 2015
- Full Text
- View/download PDF
20. Poster session 6: Saturday 6 December 2014, 08:30-12:30 * Location: Poster area
- Author
-
Goirigolzarri Artaza, J, Gallego Delgado, M, Jaimes Castellanos, CP, Cavero Gibanel, MA, Pastrana Ledesma, MA, Alonso Pulpon, LA, Gonzalez Mirelis, J, Al Ansi, R Z, Sokolovic, S, Cerin, G, Szychta, W, Popa, B A, Botezatu, D, Benea, D, Manganiello, S, Corlan, A, Jabour, A, Igual Munoz, B, Osaca Asensi, JOA, Andres La Huerta, AALH, Maceira Gonzalez, AMG, Estornell Erill, JEE, Cano Perez, OCP, Sancho-Tello, MJSTDC, Alonso Fernandez, PAF, Sepulveda Sanchez, PSS, Montero Argudo, AMA, Palombo, C, Morizzo, C, Baluci, M, Kozakova, M, Panajotu, A, Karady, J, Szeplaki, G, Horvath, T, Tarnoki, DL, Jermendy, AL, Geller, L, Merkely, B, Maurovich-Horvat, P, Group, MTA-SE "Lendület" Cardiovascular Imaging Research, Moustafa, S, Mookadam, F, Youssef, M, Zuhairy, H, Connelly, M, Prieur, T, Alvarez, N, Ashikhmin, Y, Drapkina, O, Boutsikou, M, Demerouti, E, Leontiadis, E, Petrou, E, Karatasakis, G, Kozakova, M, Morizzo, C, Bianchi, V, Marchi, B, Federico, G, Palombo, C, Chatzistamatiou, E, Moustakas, G, Memo, G, Konstantinidis, D, Mpampatzeva Vagena, I, Manakos, K, Traxanas, K, Vergi, N, Feretou, A, Kallikazaros, I, Goto, M, Uejima, T, Itatani, K, Pedrizzetti, G, Mada, RO, Daraban, AM, Duchenne, J, Voigt, JU, Chiu, D Y Y, Green, D, Johnstone, L, Sinha, S, Kalra, PA, Abidin, N, Group, Salford Vascular Research, Sikora-Frac, M, Zaborska, B, Maciejewski, P, Bednarz, B, Budaj, A, Nemes, A, Sasi, V, Gavaller, H, Kalapos, A, Domsik, P, Katona, A, Szucsborus, T, Ungi, T, Forster, T, Ungi, I, Pluchinotta, FR, Arcidiacono, C, Saracino, A, Carminati, M, Bussadori, C, Dahlslett, T, Karlsen, S, Grenne, B, Sjoli, B, Bendz, B, Skulstad, H, Smiseth, OA, Edvardsen, T, Brunvand, H, Vereckei, A, Szelenyi, ZS, Szenasi, G, Santoro, C, Galderisi, M, Niglio, T, Santoro, M, Stabile, E, Rapacciuolo, A, Spinelli, L, De Simone, G, Esposito, G, Trimarco, B, Hubert, S, Jacquier, A, Fromonot, J, Resseguier, C, Tessier, A, Guieu, R, Renard, S, Haentjiens, J, Lavoute, C, Habib, G, Menting, M E, Koopman, LP, Mcghie, JS, Rebel, B, Gnanam, D, Helbing, WA, Van Den Bosch, AE, Roos-Hesselink, JW, Shiino, K, Yamada, A, Sugimoto, K, Takada, K, Takakuwa, Y, Miyagi, M, Iwase, M, Ozaki, Y, Placido, R, Ramalho, A, Nobre E Menezes, M, Cortez-Dias, N, Goncalves, S, Guimaraes, T, Robalo Martins, S, Francisco, AR, Almeida, AG, Nunes Diogo, A, Hayashi, T, Itatani, K, Inuzuka, R, Shindo, T, Hirata, Y, Shimizu, N, Miyaji, K, Henri, C, Dulgheru, R, Magne, J, Kou, S, Davin, L, Nchimi, A, Oury, C, Pierard, L, Lancellotti, P, Kovalyova, O, Honchar, O, Tengku, WINDA, Ketaren, ANDRE, Mingo Santos, S, Monivas Palomero, V, Restrepo Cordoba, A, Rodriguez Gonzalez, E, Goirigolzarri Artaza, J, Sayago Silva, I, Garcia Lunar, I, Mitroi, C, Cavero Gibanel, M, Segovia Cubero, J, Ryu, SK, Park, JY, Kim, SH, Choi, JW, Goh, CW, Byun, YS, Choi, JH, Westholm, C, Johnson, J, Jernberg, T, Winter, R, Rio, P, Moura Branco, L, Galrinho, A, Pinto Teixeira, P, Viveiros Monteiro, A, Portugal, G, Pereira-Da-Silva, T, Afonso Nogueira, M, Abreu, J, Cruz Ferreira, R, Mazzone, A, Botto, N, Paradossi, U, Chabane, A, Francini, M, Cerone, E, Baroni, M, Maffei, S, Berti, S, Tatu-Chitoiu, G P, Deleanu, D, Macarie, C, Chioncel, O, Dorobantu, M, Udroiu, C, Calmac, L, Diaconeasa, A, Vintila, V, Vinereanu, D, investigators, RO-STEMI, Ghattas, A, Shantsila, E, Griffiths, H, Lip, GY, Galli, E, Guirette, Y, Daudin, M, Auffret, V, Mabo, P, Donal, E, Fabiani, I, Conte, L, Scatena, C, Barletta, V, Pratali, S, De Martino, A, Bortolotti, U, Naccarato, AG, Di Bello, V, Falanga, G, Alati, E, Di Giannuario, G, Zito, C, Cusma' Piccione, M, Carerj, S, Oreto, G, Dattilo, G, Alfieri, O, La Canna, G, Generati, G, Bandera, F, Pellegrino, M, Alfonzetti, E, Labate, V, Guazzi, M, Cho, EJ, Park, S-J, Lim, HJ, Yoon, HR, Chang, S-A, Lee, S-C, Park, SW, Cengiz, B, Sahin, S T, Yurdakul, S, Kahraman, S, Bozkurt, A, Aytekin, S, Borges, I P, Peixoto, ECS, Peixoto, RTS, Peixoto, RTS, Marcolla, VF, Venkateshvaran, A, Sola, S, Dash, P K, Thapa, P, Manouras, A, Winter, R, Brodin, LA, Govind, S C, Mizariene, V, Verseckaite, R, Bieseviciene, M, Karaliute, R, Jonkaitiene, R, Vaskelyte, J, Arzanauskiene, R, Janenaite, J, Jurkevicius, R, Rosner, S, Orban, M, Nadjiri, J, Lesevic, H, Hadamitzky, M, Sonne, C, Manganaro, R, Carerj, S, Cusma-Piccione, MC, Caprino, A, Boretti, I, Todaro, MC, Falanga, G, Oreto, L, D'angelo, MC, Zito, C, Le Tourneau, T, Cueff, C, Richardson, M, Hossein-Foucher, C, Fayad, G, Roussel, JC, Trochu, JN, Vincentelli, A, Obase, K, Weinert, L, Lang, R, Cavalli, G, Muraru, D, Miglioranza, MH, Addetia, K, Veronesi, F, Cucchini, U, Mihaila, S, Tadic, M, Lang, RM, Badano, L, Polizzi, V, Pino, PG, Luzi, G, Bellavia, D, Fiorilli, R, Chialastri, C, Madeo, A, Malouf, J, Buffa, V, Musumeci, F, Gripari, P, Tamborini, G, Bottari, V, Maffessanti, F, Carminati, C, Muratori, M, Vignati, C, Bartorelli, A, Alamanni, F, Pepi, M, Polymeros, S, Dimopoulos, A, Spargias, K, Karatasakis, G, Athanasopoulos, G, Pavlides, G, Dagres, N, Vavouranakis, E, Stefanadis, C, Cokkinos, DV, Pradel, S, Mohty, D, Magne, J, Darodes, N, Lavergne, D, Damy, T, Beaufort, C, Aboyans, V, Jaccard, A, Mzoughi, K, Zairi, I, Jabeur, M, Ben Moussa, F, Ben Chaabene, A, Kamoun, S, Mrabet, K, Fennira, S, Zargouni, A, Kraiem, S, Jovanova, S, Arnaudova-Dezjulovic, F, Correia, C E, Cruz, I, Marques, N, Fernandes, M, Bento, D, Moreira, D, Lopes, L, Azevedo, O, GROUP, SUNSHINE, Keramida, K, Kouris, N, Kostopoulos, V, Psarrou, G, Giannaris, V, Olympios, CD, Marketou, M, Parthenakis, F, Kalyva, N, Pontikoglou, CH, Maragkoudakis, S, Zacharis, E, Patrianakos, A, Roufas, K, Papadaki, H, Vardas, P, Dominguez Rodriguez, F, Monivas Palomero, V, Mingo Santos, S, Arribas Rivero, B, Cuenca Parra, S, Zegri Reiriz, I, Vazquez Lopez-Ibor, J, Garcia-Pavia, P, Szulik, M, Streb, W, Wozniak, A, Lenarczyk, R, Sliwinska, A, Kalarus, Z, Kukulski, T, Nemes, A, Domsik, P, Kalapos, A, Forster, T, Serra, W, Lumetti, FL, Mozzani, FM, Del Sante, GDS, Ariani, AA, Corros, C, Colunga, S, Garcia-Campos, A, Diaz, E, Martin, M, Rodriguez-Suarez, ML, Leon, V, Fidalgo, A, Moris, C, De La Hera, JM, Kylmala, M M, Rosengard-Barlund, M, Groop, P H, Lommi, J, Bruin De- Bon, HACM, Bilt Van Der, IA, Wilde, AA, Brink Van Den, RBA, Teske, AJ, Rinkel, GJ, Bouma, BJ, Teixeira, R, Monteiro, R, Garcia, J, Silva, A, Graca, M, Baptista, R, Ribeiro, M, Cardim, N, Goncalves, L, Duszanska, A, Skoczylas, I, Kukulski, T, Polonski, L, Kalarus, Z, Choi, J-H, Park, JS, Ahn, JH, Lee, JW, Ryu, SK, Ahn, J, Kim, DH, Lee, HO, Przewlocka-Kosmala, M, Mlynarczyk, J, Rojek, A, Mysiak, A, Kosmala, W, Pellissier, A, Larochelle, E, Krsticevic, L, Baron, E, Le, V, Roy, A, Deragon, A, Cote, M, Garcia, D, Tournoux, F, Yiangou, K, Azina, C, Yiangou, A, Zitti, M, Ioannides, M, Ricci, F, Dipace, G, Aquilani, R, Radico, F, Cicchitti, V, Bianco, F, Miniero, E, Petrini, F, De Caterina, R, Gallina, S, Jardim Prista Monteiro, R, Teixeira, R, Garcia, J, Baptista, R, Ribeiro, M, Cardim, N, Goncalves, L, Chung, H, Kim, JY, Joung, B, Uhm, JS, Pak, HN, Lee, MH, Lee, KY, Ragab, AM, Abdelwahab, AMIR, Yazeed, YASER, El Naggar, WAEL, Spahiu, K, Spahiu, E, Doko, A, Liesting, C, Brugts, JJ, Kofflard, MJM, Kitzen, JJEM, Boersma, E, Levin, M-D, Coppola, C, Piscopo, G, Rea, D, Maurea, C, Caronna, A, Capasso, I, Maurea, N, Azevedo, O, Tadeu, I, Lourenco, M, Portugues, J, Pereira, V, Lourenco, A, Nesukay, E, Kovalenko, V, Cherniuk, S, Danylenko, O, Muhammedov, MB, Ahmedova, DM, Hojakuliyev, BG, Atayeva, D, Nemes, A, Domsik, P, Kalapos, A, Lengyel, C, Varkonyi, TT, Orosz, A, Forster, T, Castro, M, Abecasis, J, Dores, H, Madeira, S, Horta, E, Ribeiras, R, Canada, M, Andrade, MJ, Mendes, M, Morosin, M, Piazza, R, Leonelli, V, Leiballi, E, Pecoraro, R, Cinello, M, Dell' Angela, L, Cassin, M, Sinagra, G, Nicolosi, GL, Wierzbowska-Drabik, K, Hamala, P, Kasprzak, JD, O'driscoll, J, Rossato, C, Gargallo-Fernandez, P, Araco, M, Sharma, S, Sharma, R, Jakus, N, Baricevic, Z, Ljubas Macek, J, Skoric, B, Skorak, I, Velagic, V, Separovic Hanzevacki, J, Milicic, D, Cikes, M, Deljanin Ilic, M, Ilic, S, Kocic, G, Pavlovic, R, Stoickov, V, Ilic, V, Nikolic, LJ, Generati, G, Bandera, F, Pellegrino, M, Alfonzetti, E, Labate, V, Guazzi, M, Labate, V, Bandera, F, Generati, G, Pellegrino, M, Donghi, V, Alfonzetti, E, Guazzi, M, Zakarkaite, D, Kramena, R, Aidietiene, S, Janusauskas, V, Rucinskas, K, Samalavicius, R, Norkiene, I, Speciali, G, Aidietis, A, Kemaloglu Oz, T, Ozpamuk Karadeniz, F, Akyuz, S, Unal Dayi, S, Esen Zencirci, A, Atasoy, I, Osken, A, Eren, M, Fazendas, P R, Caldeira, D, Stuart, B, Cruz, I, Rocha Lopes, L, Almeida, A R, Sousa, P, Joao, I, Cotrim, C, Pereira, H, Fazendas, P R, Caldeira, D, Stuart, B, Cruz, I, Rocha Lopes, L, Almeida, A R, Joao, I, Cotrim, C, Pereira, H, Sinem Cakal, SC, Elif Eroglu, EE, Baydar, O, Beytullah Cakal, BC, Mehmet Vefik Yazicioglu, MVY, Mustafa Bulut, MB, Cihan Dundar, CD, Kursat Tigen, KT, Birol Ozkan, BO, Ali Metin Esen, A, Yagasaki, H, Kawasaki, M, Tanaka, R, Minatoguchi, S, Houle, H, Warita, S, Ono, K, Noda, T, Watanabe, S, Minatoguchi, S, Cho, E J, Park, S J, Lim, H J, Chang, S A, Lee, S C, Park, S W, Cho, E J, Park, S J, Lim, H J, Chang, S A, Lee, S C, Park, S W, Mornos, C, Cozma, D, Ionac, A, Mornos, A, Popescu, I, Ionescu, G, Pescariu, S, Melzer, L, Faeh-Gunz, A, Seifert, B, Attenhofer Jost, C H, Storve, S, Haugen, BO, Dalen, H, Grue, JF, Samstad, S, Torp, H, Ferrarotti, L, Maggi, E, Piccinino, C, Sola, D, Pastore, F, Marino, PN, Ranjbar, S, Karvandi, M, Hassantash, SA, Karvandi, M, Ranjbar, S, Tierens, S, Remory, I, Bala, G, Gillis, K, Hernot, S, Droogmans, S, Cosyns, B, Lahoutte, T, Tran, N, Poelaert, J, Al-Mallah, M, Alsaileek, A, Nour, K, Celeng, CS, Horvath, T, Kolossvary, M, Karolyi, M, Panajotu, A, Kitslaar, P, Merkely, B, Maurovich Horvat, P, Group, MTA-SE "Lendület" Cardiovascular Imaging Research, Aguiar Rosa, S, Ramos, R, Marques, H, Portugal, G, Pereira Da Silva, T, Rio, P, Afonso Nogueira, M, Viveiros Monteiro, A, Figueiredo, L, and Cruz Ferreira, R
- Abstract
Introduction: The increase of left auricular volume (LAV) is a robust cardiovascular event predictor. Despite that echochardiography is more often used, cardiac MRI is considered more accurate. Our objetives are to validate "fast" LAV measures by MRI vs the considered gold standard (GS) and to compare Echo and MRI in a wide spectrum of patients. Methods: In a non-selected popullation with MRI study previously realized, we measured LAV by biplane method (BPMR) and by area-length in 4 chamber view (ALMR) and compared them with biplane (BPe) and discs method (MDDe) in 4 chamber view in echo. To validate MRI measurements, we measured LAV in short axis slices (Simpson Method, SM) in a group of patients and considered it the GS. Results: 186 patients were included (mean age 51 ± 17 age; 123 male; 14 in AF) with clinical indication of cardiac MRI (Philips 1,5 T). In 24 patients SM was calculated. 29% of cardiac MRI were considered normal. Mean underlying pathologies were myocardiopathy (27%), Ischemic myocardiopathy (17%), myopericarditis (10%), prior to AF ablation (4%), valvular disease (6%) and miscellaneous (7%). Excellent correlation was obtained between "fast" MRI measurements and SM in MRI (SM vs BPMR interclass correlation coefficient ICC=0.965 and SM vs ALMR, ICC=0.958; P<0.05) with low interobserver variability (ICC=0.983 for SM; ICC=0.949 for BPMR; ICC=0.931 for ALMR). "Fast" measurements by MRI showed stadistical correlation between them (CCI=0.910) (Figure). Correlation between Echo and MRI measures was only moderate. (BPRM vs BPe CCI=0,469 mean difference -30 ml; ALMR vs MDDe ICC=0,456 mean difference -24 mL). Conclusions: ‘fast’ LAV measures by MRI are comparable with the MRI GS and also between them. Echo values seem to underestimate compared to MRI, so its use may not be suitable.
- Published
- 2014
- Full Text
- View/download PDF
21. Case-based session: unusual and multitrouble cases: Saturday 6 December 2014, 08:30-10:0 * Location: Agora
- Author
-
Eissmann, M, Kahlert, P, Erbel, R, Janosi, RA, Soeholm, H, Hassager, C, Vejlstrup, N, Arendrup, H, Jensen, M, Lund, J, Ihlemann, N, Neykova, A, Molcard, D, Moulla, M, Valizadeh, R, Alghandour, M, Mahmoud, M, Shimbo, M, Watanabe, H, Iino, K, Ito, H, Piriou, N, Sassier, J, Pallardy, A, Valette, F, Serfaty, JM, Trochu, JN, Cordovil, A, Tude Rodrigues, AC, Piveta, R, De Oliveira, W, Ponchirolli, AP, Monaco, C, De Lira Filho, E, Vieira, M, Fischer, CH, and Morhy, S
- Abstract
An 83-year-old morbid woman presented with progredient dyspnoea (New York Heart Association [NYHA] stage IV) and a history of recurrent pulmonary oedema. Owing to type A aortic disection, she underwent aortic surgery 3 years prior (January 2009), which included supracoronary ascending aortic replacement and a proximal aorta-to-prosthesis anastomosis. Transthoracic echocardiography revealed major pulmonary hypertension with an estimated systolic pulmonary pressure of 70-75 mm Hg and severe tricuspid regurgitation. Further investigation, including computed tomography and 3-D transoesophageal echocardiography, revealed rupture of the aortic prothesis with a fistula of the paraprosthetic lumen to the right pulmonary artery. Because of multiple concomitant diseases and severe right-sided heart failure, an interventional approach was initiated. With a complex 3-D-echo-guided intervention, the fistula was successfully closed using a 12-mm Amplatzer ASD Occluder which resulted in a reduction in shunt volume. Postinterventional imaging showed the correct position of the occluder with only a minor residual flow. At 18 months' follow-up, the patient presented with improvement of the preexisting dyspnoea, from NYHA stage IV to NYHA stage II or III. The cardiac ultrasound result indicated a reduction in estimated systolic pulmonary pressure to 45-50 mm Hg.
Figure - Published
- 2014
- Full Text
- View/download PDF
22. Poster session Thursday 12 December - AM: 12/12/2013, 08:30-12:30 * Location: Poster area
- Author
-
Abdovic, E, Abdovic, S, Hristova, K, Hristova, K, Katova, TZ, Katova, TZ, Gocheva, N, Gocheva, N, Pavlova, M, Pavlova, M, Gurzun, M M, Ionescu, A, Canpolat, U, Yorgun, H, Sunman, H, Sahiner, L, Kaya, EB, Ozer, N, Tokgozoglu, L, Kabakci, G, Aytemir, K, Oto, A, Gonella, A, Dascenzo, F, Casasso, F, Conte, E, Margaria, F, Grosso Marra, W, Frea, S, Morello, M, Bobbio, M, Gaita, F, Seo, HY, Lee, SP, Lee, JM, Yoon, YE, Park, E, Kim, HK, Park, SJ, Lee, H, Kim, YJ, Sohn, DW, Nemes, A, Domsik, P, Kalapos, A, Orosz, A, Lengyel, C, Forster, T, Enache, R, Muraru, D, Popescu, BA, Calin, A, Nastase, O, Botezatu, D, Purcarea, F, Rosca, M, Beladan, CC, Ginghina, C, Canpolat, U, Aytemir, K, Ozer, N, Yorgun, H, Sahiner, L, Kaya, EB, Oto, A, Trial, Turkish Atrial Fibrosis, Muraru, D, Piasentini, E, Mihaila, S, Padayattil Jose, S, Peluso, D, Ucci, L, Naso, P, Puma, L, Iliceto, S, Badano, LP, Cikes, M, Jakus, N, Sutherland, GR, Haemers, P, Dhooge, J, Claus, P, Yurdakul, S, Oner, FATMA, Direskeneli, HANER, Sahin, TAYLAN, Cengiz, BETUL, Ercan, G, Bozkurt, AYSEN, Aytekin, SAIDE, Osa Saez, A M, Rodriguez-Serrano, M, Lopez-Vilella, R, Buendia-Fuentes, F, Domingo-Valero, D, Quesada-Carmona, A, Miro-Palau, VE, Arnau-Vives, MA, Palencia-Perez, M, Rueda-Soriano, J, Lipczynska, M, Piotr Szymanski, PS, Anna Klisiewicz, AK, Lukasz Mazurkiewicz, LM, Piotr Hoffman, PH, Kim, KH, Cho, SK, Ahn, Y, Jeong, MH, Cho, JG, Park, JC, Chinali, M, Franceschini, A, Matteucci, MC, Doyon, A, Esposito, C, Del Pasqua, A, Rinelli, G, Schaefer, F, group, the 4C study, Kowalik, E, Klisiewicz, A, Rybicka, J, Szymanski, P, Biernacka, EK, Hoffman, P, Lee, S, Kim, W, Yun, H, Jung, L, Kim, E, Ko, J, Ruddox, V, Norum, IB, Edvardsen, T, Baekkevar, M, Otterstad, JE, Erdei, T, Edwards, J, Braim, D, Yousef, Z, Fraser, AG, Cardiff, Investigators, MEDIA, Melcher, A, Reiner, B, Hansen, A, Strandberg, LE, Caidahl, K, Wellnhofer, E, Kriatselis, C, Gerd-Li, H, Furundzija, V, Thnabalasingam, U, Fleck, E, Graefe, M, Park, YJ, Moon, JG, Ahn, TH, Baydar, O, Kadriye Kilickesmez, KK, Ugur Coskun, UC, Polat Canbolat, PC, Veysel Oktay, VO, Umit Yasar Sinan, US, Okay Abaci, OA, Cuneyt Kocas, CK, Sinan Uner, SU, Serdar Kucukoglu, SK, Ferferieva, V, Claus, P, Rademakers, F, Dhooge, J, Le, T T, Wong, P, Tee, N, Huang, F, Tan, RS, Altman, M, Logeart, D, Bergerot, C, Gellen, B, Pare, C, Gerard, S, Sirol, M, Vicaut, E, Mercadier, JJ, Derumeaux, G A, investigators, PREGICA, Park, T-H, Park, J-I, Shin, S-W, Yun, S-H, Lee, J-E, Makavos, G, Kouris, N, Keramida, K, Dagre, A, Ntarladimas, I, Kostopoulos, V, Damaskos, D, Olympios, CD, Leong, DP, Piers, SRD, Hoogslag, GE, Hoke, U, Thijssen, J, Ajmone Marsan, N, Schalij, MJ, Bax, JJ, Zeppenfeld, K, Delgado, V, Rio, P, Branco, L, Galrinho, A, Cacela, D, Abreu, J, Timoteo, A, Teixeira, P, Pereira-Da-Silva, T, Selas, M, Cruz Ferreira, R, Popa, B A, Zamfir, L, Novelli, E, Lanzillo, G, Karazanishvili, L, Musica, G, Stelian, E, Benea, D, Diena, M, Cerin, G, Fusini, L, Mirea, O, Tamborini, G, Muratori, M, Gripari, P, Ghulam Ali, S, Cefalu, C, Maffessanti, F, Andreini, D, Pepi, M, Mamdoo, F, Goncalves, A, Peters, F, Matioda, H, Govender, S, Dos Santos, C, Essop, MR, Kuznetsov, V A, Yaroslavskaya, E I, Pushkarev, G S, Krinochkin, D V, Kolunin, G V, Bennadji, A, Hascoet, S, Dulac, Y, Hadeed, K, Peyre, M, Ricco, L, Clement, L, Acar, P, Ding, WH, Zhao, Y, Lindqvist, P, Nilson, J, Winter, R, Holmgren, A, Ruck, A, Henein, MY, Illatopa, V, Cordova, F, Espinoza, D, Ortega, J, Cavalcante, JL, Patel, MT, Katz, W, Schindler, J, Crock, F, Khanna, MK, Khandhar, S, Tsuruta, H, Kohsaka, S, Murata, M, Yasuda, R, Tokuda, H, Kawamura, A, Maekawa, Y, Hayashida, K, Fukuda, K, Le Tourneau, T, Kyndt, F, Lecointe, S, Duval, D, Rimbert, A, Merot, J, Trochu, JN, Probst, V, Le Marec, H, Schott, JJ, Veronesi, F, Addetia, K, Corsi, C, Lamberti, C, Lang, RM, Mor-Avi, V, Gjerdalen, G F, Hisdal, J, Solberg, EE, Andersen, TE, Radunovic, Z, Steine, K, Maffessanti, F, Gripari, P, Tamborini, G, Muratori, M, Fusini, L, Ferrari, C, Caiani, EG, Alamanni, F, Bartorelli, AL, Pepi, M, Dascenzi, F, Cameli, M, Iadanza, A, Lisi, M, Reccia, R, Curci, V, Sinicropi, G, Henein, M, Pierli, C, Mondillo, S, Rekhraj, S, Hoole, SP, Mcnab, DC, Densem, CG, Boyd, J, Parker, K, Shapiro, LM, Rana, BS, Kotrc, M, Vandendriessche, T, Bartunek, J, Claeys, MJ, Vanderheyden, M, Paelinck, B, De Bock, D, De Maeyer, C, Vrints, C, Penicka, M, Silveira, C, Albuquerque, ESA, Lamprea, DL, Larangeiras, VL, Moreira, CRPM, Victor Filho, MVF, Alencar, BMA, Silveira, AQMS, Castillo, JMDC, Zambon, E, Iorio, A, Carriere, C, Pantano, A, Barbati, G, Bobbo, M, Abate, E, Pinamonti, B, Di Lenarda, A, Sinagra, G, Salemi, V M C, Tavares, L, Ferreira Filho, JCA, Oliveira, AM, Pessoa, FG, Ramires, F, Fernandes, F, Mady, C, Cavarretta, E, Lotrionte, M, Abbate, A, Mezzaroma, E, De Marco, E, Peruzzi, M, Loperfido, F, Biondi-Zoccai, G, Frati, G, Palazzoni, G, Park, T-H, Lee, J-E, Lee, D-H, Park, J-S, Park, K, Kim, M-H, Kim, Y-D, Van T Sant, J, Gathier, WA, Leenders, GE, Meine, M, Doevendans, PA, Cramer, MJ, Poyhonen, P, Kivisto, S, Holmstrom, M, Hanninen, H, Schnell, F, Betancur, J, Daudin, M, Simon, A, Carre, F, Tavard, F, Hernandez, A, Garreau, M, Donal, E, Calore, C, Muraru, D, Badano, LP, Melacini, P, Mihaila, S, Denas, G, Naso, P, Casablanca, S, Santi, F, Iliceto, S, Aggeli, C, Venieri, E, Felekos, I, Anastasakis, A, Ritsatos, K, Kakiouzi, V, Kastellanos, S, Cutajar, I, Stefanadis, C, Palecek, T, Honzikova, J, Poupetova, H, Vlaskova, H, Kuchynka, P, Linhart, A, Elmasry, O, Mohamed, MH, Elguindy, WM, Bishara, PNI, Garcia-Gonzalez, P, Cozar-Santiago, P, Bochard-Villanueva, B, Fabregat-Andres, O, Cubillos-Arango, A, Valle-Munoz, A, Ferrer-Rebolleda, J, Paya-Serrano, R, Estornell-Erill, J, Ridocci-Soriano, F, Jensen, M, Havndrup, O, Christiansen, M, Andersen, PS, Axelsson, A, Kober, L, Bundgaard, H, Karapinar, H, Kaya, A, Uysal, EB, Guven, AS, Kucukdurmaz, Z, Oflaz, MB, Deveci, K, Sancakdar, E, Gul, I, Yilmaz, A, Tigen, M K, Karaahmet, T, Dundar, C, Yalcinsoy, M, Tasar, O, Bulut, M, Takir, M, Akkaya, E, Jedrzejewska, I, Braksator, W, Krol, W, Swiatowiec, A, Dluzniewski, M, Lipari, P, Bonapace, S, Zenari, L, Valbusa, F, Rossi, A, Lanzoni, L, Molon, G, Canali, G, Campopiano, E, Barbieri, E, Rueda Calle, E, Alfaro Rubio, F, Gomez Gonzalez, J, Gonzalez Santos, P, Cameli, M, Lisi, M, Focardi, M, Dascenzi, F, Solari, M, Galderisi, M, Mondillo, S, Pratali, L, Bruno, R M, Corciu, AI, Comassi, M, Passera, M, Gastaldelli, A, Mrakic-Sposta, S, Vezzoli, A, Picano, E, Perry, R, Penhall, A, De Pasquale, C, Selvanayagam, J, Joseph, M, Simova, I I, Katova, T M, Kostova, V, Hristova, K, Lalov, I, Dascenzi, F, Pelliccia, A, Natali, BM, Cameli, M, Alvino, F, Zorzi, A, Corrado, D, Bonifazi, M, Mondillo, S, Rees, E, Rakebrandt, F, Rees, DA, Halcox, JP, Fraser, AG, Odriscoll, J, Lau, N, Perez-Lopez, M, Sharma, R, Lichodziejewska, B, Goliszek, S, Kurnicka, K, Kostrubiec, M, Dzikowska Diduch, O, Krupa, M, Grudzka, K, Ciurzynski, M, Palczewski, P, Pruszczyk, P, Gheorghe, LL, Castillo Ortiz, J, Del Pozo Contreras, R, Calle Perez, G, Sancho Jaldon, M, Cabeza Lainez, P, Vazquez Garcia, R, Fernandez Garcia, P, Chueca Gonzalez, E, Arana Granados, R, Zhao, XX, Xu, XD, Bai, Y, Qin, YW, Leren, IS, Hasselberg, NE, Saberniak, J, Leren, TP, Edvardsen, T, Haugaa, KH, Daraban, A M, Sutherland, GR, Claus, P, Werner, B, Gewillig, M, Voigt, JU, Santoro, A, Ierano, P, De Stefano, F, Esposito, R, De Palma, D, Ippolito, R, Tufano, A, Galderisi, M, Costa, R, Fischer, C, Rodrigues, A, Monaco, C, Lira Filho, E, Vieira, M, Cordovil, A, Oliveira, E, Mohry, S, Gaudron, P, Niemann, M, Herrmann, S, Strotmann, J, Beer, M, Hu, K, Bijnens, B, Ertl, G, Weidemann, F, Baktir, AO, Sarli, B, Cicek, M, Karakas, MS, Saglam, H, Arinc, H, Akil, MA, Kaya, H, Ertas, F, Bilik, MZ, Yildiz, A, Oylumlu, M, Acet, H, Aydin, M, Yuksel, M, Alan, S, Odriscoll, J, Gravina, A, Di Fino, S, Thompson, M, Karthigelasingham, A, Ray, K, Sharma, R, De Chiara, B, Russo, CF, Alloni, M, Belli, O, Spano, F, Botta, L, Palmieri, B, Martinelli, L, Giannattasio, C, Moreo, A, Mateescu, AD, La Carrubba, S, Vriz, O, Di Bello, V, Carerj, S, Zito, C, Ginghina, C, Popescu, BA, Nicolosi, GL, Antonini-Canterin, F, Malev, E, Omelchenko, M, Vasina, L, Luneva, E, Zemtsovsky, E, Cikes, M, Velagic, V, Gasparovic, H, Kopjar, T, Colak, Z, Hlupic, LJ, Biocina, B, Milicic, D, Tomaszewski, A, Kutarski, A, Poterala, M, Tomaszewski, M, Brzozowski, W, Kijima, Y, Akagi, T, Nakagawa, K, Ikeda, M, Watanabe, N, Ueoka, A, Takaya, Y, Oe, H, Toh, N, Ito, H, Bochard Villanueva, B, Paya-Serrano, R, Fabregat-Andres, O, Garcia-Gonzalez, P, Perez-Bosca, JL, Cubillos-Arango, A, Chacon-Hernandez, N, Higueras-Ortega, L, De La Espriella-Juan, R, Ridocci-Soriano, F, Noack, T, Mukherjee, C, Ionasec, RI, Voigt, I, Kiefer, P, Hoebartner, M, Misfeld, M, Mohr, F-W, Seeburger, J, Daraban, A M, Baltussen, L, Amzulescu, MS, Bogaert, J, Jassens, S, Voigt, JU, Duchateau, N, Giraldeau, G, Gabrielli, L, Penela, D, Evertz, R, Mont, L, Brugada, J, Berruezo, A, Bijnens, BH, Sitges, M, Yoshikawa, H, Suzuki, M, Hashimoto, G, Kusunose, Y, Otsuka, T, Nakamura, M, Sugi, K, Ruiz Ortiz, M, Mesa, D, Romo, E, Delgado, M, Seoane, T, Martin, M, Carrasco, F, Lopez Granados, A, Arizon, JM, Suarez De Lezo, J, Magalhaes, A, Cortez-Dias, N, Silva, D, Menezes, M, Saraiva, M, Santos, L, Costa, A, Costa, L, Nunes Diogo, A, Fiuza, M, Ren, B, De Groot-De Laat, LE, Mcghie, J, Vletter, WB, Geleijnse, ML, Toda, H, Oe, H, Osawa, K, Miyoshi, T, Ugawa, S, Toh, N, Nakamura, K, Kohno, K, Morita, H, Ito, H, El Ghannudi, S, Germain, P, Samet, H, Jeung, M, Roy, C, Gangi, A, Orii, M, Hirata, K, Yamano, T, Tanimoto, T, Ino, Y, Yamaguchi, T, Kubo, T, Imanishi, T, Akasaka, T, Sunbul, M, Kivrak, T, Oguz, M, Ozguven, S, Gungor, S, Dede, F, Turoglu, HT, Yildizeli, B, Mutlu, B, Mihaila, S, Muraru, D, Piasentini, E, Peluso, D, Cucchini, U, Casablanca, S, Naso, P, Iliceto, S, Vinereanu, D, Badano, LP, Rodriguez Munoz, DA, Moya Mur, JL, Becker Filho, D, Gonzalez, A, Casas Rojo, E, Garcia Martin, A, Recio Vazquez, M, Rincon, LM, Fernandez Golfin, C, Zamorano Gomez, JL, Ledakowicz-Polak, A, Polak, L, Zielinska, M, Kamiyama, T, Nakade, T, Nakamura, Y, Ando, T, Kirimura, M, Inoue, Y, Sasaki, O, Nishioka, T, Farouk, H, Sakr, B, Elchilali, K, Said, K, Sorour, K, Salah, H, Mahmoud, G, Casanova Rodriguez, C, Cano Carrizal, R, Iglesias Del Valle, D, Martin Penato Molina, A, Garcia Garcia, A, Prieto Moriche, E, Alvarez Rubio, J, De Juan Bagua, J, Tejero Romero, C, Plaza Perez, I, Korlou, P, Stefanidis, A, Mpikakis, N, Ikonomidis, I, Anastasiadis, S, Komninos, K, Nikoloudi, P, Margos, P, and Pentzeridis, P
- Abstract
Purpose: Atrial fibrillation (AF) is the most prevalent sustained arrhythmia. It is a disease of the elderly and it is common in patients (pts) with structural heart disease. Hypertension (HA), hypertensive heart disease (HHD), diabetes mellitus (DM), coronary artery disease (CAD), heart failure (HF), and valvular heart disease (VHD) are recognized predisposing factors to AF. Objectives: To echocardiographicly disclose the most common predisposing morbidities to AF in our population sample. Methods: From June 2000 to February 2013, 3755 consecutive pts with AF were studied during echocardiographic check-up. According to transthoracic echo, pts were divided in groups based on dominative underlying heart diseases. Electrocardiographically documented AF was subdivided in two groups: transitory and chronic. Transitory AF fulfilled criteria for paroxysmal or persistent AF. Chronic AF were cases of long-standing persistent or permanent AF. Results: The median age was 72 years, age range between 16 and 96 years. There were 51.4% of females. Chronic AF was observed in 68.3% pts. Distribution of underlying heart diseases is shown in figure. Lone AF was diagnosed in only 25 pts, mostly in younger males (median age 48 years, range 29–59, men 80%). Chronic AF was predominant in groups with advanced cardiac remodeling such as dilatative cardiomyopaty (DCM) and VHD, mostly in elderly. HA and DM were found in 75.4% and 18.8%, respectively. Almost 1/2 of pts with AF had HF and 59.2% had diastolic HF. Conclusion: Up to now, echocardiographic categorization of the predisposing factors to AF was not reported. Echocardiographic evaluation of patients with AF could facilitate in identification and well-timed treatment of predisposing comorbidites.
Figure Etiological distribution of AF - Published
- 2013
- Full Text
- View/download PDF
23. Cardiac resynchronization for asymptomatic or mildly symptomatic heart failure: a bridge too far?
- Author
-
Leclercq C, Mabo P, Trochu JN, Leclercq, Christophe, Mabo, Philippe, and Trochu, Jean Noel
- Published
- 2008
- Full Text
- View/download PDF
24. Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.
- Author
-
Fauvel C, Damy T, Berthelot E, Bauer F, Eicher JC, de Groote P, Trochu JN, Picard F, Renard S, Bouvaist H, Logeart D, Roubille F, Sitbon O, and Lamblin N
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prognosis, Prospective Studies, Cardiac Catheterization methods, Prevalence, Heart Failure complications, Heart Failure physiopathology, Heart Failure epidemiology, Hypertension, Pulmonary physiopathology, Hypertension, Pulmonary diagnosis, Vascular Resistance physiology
- Abstract
Background and Aims: Based on retrospective studies, the 2022 European guidelines changed the definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF) by lowering the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). However, the impact of this definition and its prognostic value has never been evaluated prospectively., Methods: Stable left HF patients with the need for right heart catheterization were enrolled from 2010 to 2018 and prospectively followed up in this multicentre study. The impact of the successive pcPH definitions on pcPH prevalence and subgroup [i.e. isolated (IpcPH) vs. combined pcPH (CpcPH)] was evaluated. Multivariable Cox regression analysis was used to assess the prognostic value of mPAP and PVR on all-cause death or hospitalization for HF (primary outcome)., Results: Included were 662 HF patients were (median age 63 years, 60% male). Lowering mPAP from 25 to 20 mmHg resulted in +10% increase in pcPH prevalence, whereas lowering PVR from 3 to 2 resulted in +60% increase in CpcPH prevalence (with significant net reclassification improvement for the primary outcome). In multivariable analysis, both mPAP and PVR remained associated with the primary outcome [hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.00-1.03, P = .01; HR 1.07, 95% CI 1.00-1.14, P = .03]. The best PVR threshold associated with the primary outcome was around 2.2 WU. Using the 2022 definition, pcPH patients had worse survival compared with HF patients without pcPH (log-rank, P = .02) as well as CpcPH compared with IpcPH (log-rank, P = .003)., Conclusions: This study is the first emphasizing the impact of the new pcPH definition on CpcPH prevalence and validating the prognostic value of mPAP > 20 mmHg and PVR > 2 WU among HF patients., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
25. Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation: 3-Year Outcomes From the TRILUMINATE Study.
- Author
-
Nickenig G, Lurz P, Sorajja P, von Bardeleben RS, Sitges M, Tang GHL, Hausleiter J, Trochu JN, Näbauer M, Heitkemper M, Ying SW, Weber M, and Hahn RT
- Abstract
Background: Tricuspid regurgitation (TR) is a common valve disease that has a significant impact on patients' quality of life., Objectives: This study sought to report the final 3-year outcomes of tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip (Abbott) implant from the TRILUMINATE (TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR) study for the treatment of severe symptomatic TR., Methods: The TRILUMINATE study (N = 98 subjects) is an international, prospective, single-arm, multicenter study to investigate the safety and performance of T-TEER with the TriClip implant in patients with symptomatic moderate or greater TR. Echocardiographic assessments were performed at a core laboratory., Results: At 3 years, TR was reduced to moderate or less in 79% of subjects, and a reduction of at least 1 grade was achieved in 92% of subjects. TR reduction achieved at 1 year was sustained through 3 years. Subjects also experienced an improvement in heart failure symptoms assessed by NYHA functional class and quality of life assessed by the Kansas City Cardiomyopathy Questionnaire at 3 years compared to baseline. The site-reported heart failure hospitalization rate decreased from 0.43 events/patient-year 1 year before device implantation to 0.06 events/patient-year 1 year after device implantation, representing a reduction of 86% (P < 0.0001)., Conclusions: In the longest follow-up to date of any T-TEER therapy, the TRILUMINATE study demonstrated that the TriClip procedure is both safe and effective, with sustained benefits at 3 years in subjects with symptomatic moderate or greater TR. (TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR [TRILUMINATE]; NCT03227757)., Competing Interests: Funding Support and Author Disclosures This study was supported by Abbott Structural Heart. Dr Nickenig has received research funding and honoraria from Abbott, Edwards Lifesciences, and Medtronic; and has participated in clinical trials with Abbott, Edwards Lifesciences, and Medtronic. Dr Lurz has served as a consultant for Abbott Structural Heart, Edwards Lifesciences, Medtronic, ReCor, and Occlutech. Dr Sorajja has served as a consultant for 4C Medical, Abbott Structural, Adona, Boston Scientific, Edwards Lifesciences, Foldax, GE Medical, GLG, Medtronic, Phillips, Siemens, WL Gore, vDyne, and xDot; and has received personal fees from Abbott Vascular (outside the submitted work). Dr von Bardeleben has received institutional research grants and speaker honorarium from Abbott Vascular and Edwards Lifesciences; and has received nonfinancial trial support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Lifetec, and Medtronic. Dr Sitges has served as a consultant for Abbott, Edwards Lifesciences, Metronic, and General Electric; has received speaker honoraria from Abbott, Edwards Lifesciences, Medtronic, and General Electric; and has received speaker honoraria and travel and grant support from Abbott. Dr Hausleiter has received speaker honoraria and research support from Abbott Vascular and Edwards Lifesciences. Dr Trochu has received speaker honoraria, travel support, and grant support from Abbott and Novartis; has received honoraria for lectures or advisory boards from Amgen, Bayer, and Resmed; and has been an unpaid member of the Corvia Medical Scientific Advisory Group. Dr Näbauer has received speaker honoraria from Abbott. Dr Heitkemper is an employee of Abbott. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; and has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Rationale and design of the French Observatory of Acute Heart Failure (OFICA2).
- Author
-
Bouleti C, Alos B, Legallois D, Eschalier R, Costa J, Tea V, Trochu JN, Turlotte G, Perrin-Faurie J, Dutoiu T, Picard F, Ducrocq G, de Groote P, Laperche T, Delmas C, Cohen A, Doublet M, and Logeart D
- Abstract
Background: Acute heart failure (AHF) is a leading cause of hospitalization and mortality - especially in patients aged≥65 years in high-income countries - and represents a high healthcare burden. In the past decade, the epidemiology and management of heart failure (HF) has changed, with the emergence of new medical and interventional therapeutics, but up-to-date real-life data are scarce., Aims: The main objectives are to describe baseline characteristics (with an emphasis on lifestyle, cognitive status, HF knowledge and treatment adherence), management, and in-hospital and mid-term outcomes of AHF patients in France. Secondary objectives are to investigate determinants of prognosis, modalities of treatment and follow-up, and identify gaps between guidelines and real-life management., Methods: OFICA2 is a prospective multicentre observational survey that enrolled 1513 patients hospitalized for AHF in 80 participating centres in France during March and April 2021. The diagnosis of AHF was made according to the European Society of Cardiology guidelines definition. Inclusion criteria were age≥18years, health coverage and consent to participate. Detailed information was collected prospectively starting at admission. Thanks to direct linking with the French National Health Database, the anteriority up to 2years before inclusion, as well as a 3-year follow-up is specified for each patient and includes individual information on death, hospital admissions, major clinical events, drug delivery and use of reimbursed health resources., Conclusion: This cohort provides a representative snapshot on contemporary AHF, with a particular focus on self-care determinants, and will improve knowledge about AHF presentation, management and outcomes., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
27. Description of the Two-Dimensional Layer-Specific Strain Echocardiography Phenotype of Arrhythmogenic Left Ventricular Cardiomyopathy.
- Author
-
Grimault D, Serfaty JM, Guyomarch B, Marteau L, Goudal A, Schmitt S, Warin-Fresse K, Clero S, Fellah I, Thollet A, Probst V, Le Tourneau T, Trochu JN, and Piriou N
- Abstract
Background: Arrhythmogenic left ventricular cardiomyopathy (ALVC) is characterized by fibrofatty myocardial replacement demonstrated on cardiac magnetic resonance by late gadolinium enhancement (LGE) mainly involving the subepicardium. The aims of this study were to describe the layer-specific strain (LSS) echocardiography phenotype of ALVC and to compare it with LGE features., Methods: All consecutive ALVC pathogenic genetic variant carriers and noncarrier relatives were separated into four prespecified groups (overt ALVC [group 1], isolated LGE [group 2], pathogenic genetic variant carrier without ALVC phenotype [group 3], and no genetic variant carrier [group 4]) and studied accordingly using cardiac magnetic resonance and LSS echocardiography., Results: Eighty-five individuals were included. Endocardial global longitudinal strain (GLS)-epicardial GLS (GLSepi) gradient was altered predominantly in group 1, illustrating transmural strain alteration in overt ALVC (3.8 ± 1.1 in group 1, 4.3 ± 2.2 in group 2, 5.2 ± 1.2 in group 3, and 5.4 ± 1.6 in group 4; P = .0017), whereas GLSepi was impaired predominantly in group 2 (endocardial GLS and GLSepi were 15.0 ± 4.1% and 11.2 ± 3.3%, respectively, in group 1; 20.5 ± 2.8% and 16.2 ± 5.5% in group 2; 23.4 ± 3.3% and 18.2 ± 2.7% in group 3; and 24.6 ± 2.8% and 19.2 ± 1.9% in group 4; P < .0001 for all). GLSepi was able to detect subepicardial LGE in genetic variant carriers without overt ALVC with an area under curve of 0.84 (95% CI, 0.73-0.95). However, segmental epicardial and endocardial strain behaved similarly and showed comparable diagnostic values for segmental LGE detection (areas under the curve, 0.72; [95% CI, 0.69-0.76] and 0.73 [95% CI, 0.70-0.76], respectively, P = .40)., Conclusions: LSS alteration in ALVC progresses from the epicardium to the endocardium along with disease severity. Irrespective of LSS analysis, which did not provide incremental diagnostic value for the detection and localization of LGE, strain echocardiography was shown to be a potential surrogate marker of LGE, including in apparently healthy individuals with isolated LV fibrosis., (Copyright © 2024 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Chronic heart failure with reduced EF: A decade of major pharmacological innovations.
- Author
-
Trochu JN
- Subjects
- Humans, Chronic Disease, Comorbidity, Quality of Life, Heart Failure drug therapy, Heart Failure etiology, Renal Insufficiency, Chronic complications
- Abstract
Background and Objectives: Because of its severity, prevalence, and medical economic importance, heart failure is a chronic disease that is the subject of intense medical research. The aim of this article was to review the therapeutic innovations of the last decade that have been incorporated into the latest international recommendations for the treatment of heart failure., Method: Review of literature and current guidelines., Conclusion: The results of the clinical trials reviewed here represent major advances that will have a significant impact on quality of life, survival, rehospitalisation and, for certain treatments, a beneficial joint effect on commonly associated comorbidities such as diabetes and chronic renal failure., Competing Interests: Declaration of Competing Interest Jean-Noël Trochu received grants from Boston Scientific, European Union H2020, consulting fees from Bayer, Bristol-Myers-Squibb, Abbott, AstraZeneca, Novartis, lecture fees from Boehringer-Ingelheim, Vifor and congress support from Corvia., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Patterns of left ventricular remodeling post-myocardial infarction, determinants, and outcome.
- Author
-
Logeart D, Taille Y, Derumeaux G, Gellen B, Sirol M, Galinier M, Roubille F, Georges JL, Trochu JN, Launay JM, Vodovar N, Bauters C, Vicaut E, and Mercadier JJ
- Abstract
Aim: Left ventricular remodeling (LVR) after myocardial infarction (MI) can lead to heart failure, arrhythmia, and death. We aim to describe adverse LVR patterns at 6 months post-MI and their relationships with subsequent outcomes and to determine baseline., Methods and Results: A multicenter cohort of 410 patients (median age 57 years, 87% male) with reperfused MI and at least 3 akinetic LV segments on admission was analyzed. All patients had transthoracic echocardiography performed 4 days and 6 months post-MI, and 214 also had cardiac magnetic resonance imaging performed on day 4. To predict LVR, machine learning methods were employed in order to handle many variables, some of which may have complex interactions. Six months post-MI, echocardiographic increases in LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), and LV ejection fraction (LVEF) were 14.1% [interquartile range 0.0, 32.0], 5.0% [- 14.0, 25.8], and 8.7% [0.0, 19.4], respectively. At 6 months, ≥ 15% or 20% increases in LVEDV were observed in 49% and 42% of patients, respectively, and 37% had an LVEF < 50%. The rate of death or new-onset HF at the end of 5-year follow-up was 8.8%. Baseline variables associated with adverse LVR were determined best by random forest analysis and included stroke volume, stroke work, necrosis size, LVEDV, LVEF, and LV afterload, the latter assessed by Ea or Ea/Ees. In contrast, baseline clinical and biological characteristics were poorly predictive of LVR. After adjustment for predictive baseline variables, LV dilation > 20% and 6-month LVEF < 50% were significantly associated with the risk of death and/or heart failure: hazard ratio (HR) 2.12 (95% confidence interval (CI) 1.05-4.43; p = 0.04) and HR 2.68 (95% CI 1.20-6.00; p = 0.016) respectively., Conclusion: Despite early reperfusion and cardioprotective therapy, adverse LVR remains frequent after acute MI and is associated with a risk of death and HF. A machine learning approach identified and prioritized early variables that are associated with adverse LVR and which were mainly hemodynamic, combining LV volumes, estimates of systolic function, and afterload., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
- Published
- 2024
- Full Text
- View/download PDF
30. Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation.
- Author
-
Mewton N, Donal E, Picard F, Derimay F, Grinberg D, Boulch DM, Bochaton T, Piriou N, De Lorgeril A, Samson G, Rouleau F, Riche B, and Trochu JN
- Abstract
Background: Our aim was to assess the distribution of primary (with no trigger) and secondary (with a decompensation trigger) heart failure events in a severe heart failure population and their association with 2-year all-cause mortality in the Mitra.Fr study., Methods: We included 304 patients with symptomatic heart failure, and severe mitral regurgitation and guideline directed medical therapy randomized to medical therapy alone or medical therapy with percutaneous mitral valve repair. According to the follow-up, we defined 3 categories of events: follow-up without any heart failure event, at least 1 decompensation starting with a primary heart failure decompensation or starting with a precipitated secondary heart failure event. The primary outcome was 2-years all-cause mortality., Results: A total of 179 patients (59 %) had at least 1 heart failure decompensation within 24-months of follow-up. 129 heart failure decompensations (72%) were a first primary heart failure and 50 (28%) were a first secondary decompensation. Finally, 30 patients had both types of decompensations but these were not taken into account for the comparison of primary and secondary decompensations. Primary decompensations were 3-times more frequent than secondary decompensations, but the mean number of heart failure decompensations was similar in the "Primary heart failure group" compared to the "Secondary heart failure group": (1.94 ± 1.39 vs 1.80 ± 1.07 respectively; P = .480). Compared to patients without heart failure decompensation, patients with "Only primary decompensation" or with "Only secondary decompensation" had a significantly increased risk of death (HR = 4.87, 95% CI [2.86, 8.32] and 2.68 95%CI [1.64, 4.37] respectively). All-cause mortality, was not significantly different between these 2 type of decompensations (HR = 1.82, 95% CI [0.93, 3.58]; P = .082), but each additional heart failure recurrence was associated with a significant increase in mortality risk (HR = 1.27, 95% CI [1.08; 1.50]; P = .005)., Conclusions: In heart failure with reduced ejection fraction and severe secondary mitral regurgitation patients, primary heart failure decompensations were 3-times more frequent compared to precipitated decompensations with a nonsignificant trend in increased risk of all-cause mortality. Our results fail to support the differentiation between primary and secondary decompensations as they seem to portend the same outcome impact., Competing Interests: Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial.
- Author
-
Balligand JL, Brito D, Brosteanu O, Casadei B, Depoix C, Edelmann F, Ferreira V, Filippatos G, Gerber B, Gruson D, Hasenclever D, Hellenkamp K, Ikonomidis I, Krakowiak B, Lhommel R, Mahmod M, Neubauer S, Persu A, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, and Pouleur AC
- Subjects
- Female, Humans, Male, Middle Aged, Adrenergic Agonists therapeutic use, Hypertrophy, Left Ventricular, Prospective Studies, Aged, Diabetes Mellitus, Type 2, Heart Failure drug therapy
- Abstract
Importance: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling., Objective: To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF., Design, Setting, and Participants: The Beta3-LVH prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial enrolled patients between September 12, 2016, and February 26, 2021, with a follow-up of 12 months. The trial was conducted at 10 academic hospitals in 8 countries across Europe (Germany, Poland, France, Belgium, Italy, Portugal, Greece, and the UK). Patients aged 18 years or older with or without HF symptoms (maximum New York Heart Association class II) were screened for the presence of LV hypertrophy (increased LV mass index [LVMI] of ≥95 g/m2 for women or ≥115 g/m2 for men) or maximum wall thickness of 13 mm or greater using echocardiography. Data analysis was performed in August 2022., Intervention: Participants were randomly assigned (1:1) to mirabegron (50 mg/d) or placebo, stratified by the presence of atrial fibrillation and/or type 2 diabetes, for 12 months., Main Outcomes and Measures: The primary end points were LVMI determined using cardiac magnetic resonance imaging and LV diastolic function (early diastolic tissue Doppler velocity [E/e'] ratio assessed using Doppler echocardiography) at 12 months. Patients with at least 1 valid measurement of either primary end point were included in the primary analysis. Safety was assessed for all patients who received at least 1 dose of study medication., Results: Of the 380 patients screened, 296 were enrolled in the trial. There were 147 patients randomized to mirabegron (116 men [79%]; mean [SD] age, 64.0 [10.2] years) and 149 to placebo (112 men [75%]; mean [SD] age, 62.2 [10.9] years). All patients were included in the primary intention-to-treat analysis. At 12 months, the baseline and covariate-adjusted differences between groups included a 1.3-g/m2 increase in LVMI (95% CI, -0.15 to 2.74; P = .08) and a -0.15 decrease in E/e' (95% CI, -0.69 to 0.4; P = .60). A total of 213 adverse events (AEs) occurred in 82 mirabegron-treated patients (including 31 serious AEs in 19 patients) and 215 AEs occurred in 88 placebo-treated patients (including 30 serious AEs in 22 patients). No deaths occurred during the trial., Conclusions: In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms., Trial Registration: ClinicalTrials.gov Identifier: NCT02599480.
- Published
- 2023
- Full Text
- View/download PDF
32. Machine Learning-Based Phenogrouping in MVP Identifies Profiles Associated With Myocardial Fibrosis and Cardiovascular Events.
- Author
-
Huttin O, Girerd N, Jobbe-Duval A, Constant Dit Beaufils AL, Senage T, Filippetti L, Cueff C, Duarte K, Fraix A, Piriou N, Mandry D, Pace N, Le Scouarnec S, Capoulade R, Echivard M, Sellal JM, Marrec M, Beaumont M, Hossu G, Trochu JN, Sadoul N, Marie PY, Guenancia C, Schott JJ, Roussel JC, Serfaty JM, Selton-Suty C, and Le Tourneau T
- Subjects
- Humans, Adult, Middle Aged, Aged, Predictive Value of Tests, Fibrosis, Echocardiography, Mitral Valve Prolapse, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency complications, Cardiomyopathies complications
- Abstract
Background: Structural changes and myocardial fibrosis quantification by cardiac imaging have become increasingly important to predict cardiovascular events in patients with mitral valve prolapse (MVP). In this setting, it is likely that an unsupervised approach using machine learning may improve their risk assessment., Objectives: This study used machine learning to improve the risk assessment of patients with MVP by identifying echocardiographic phenotypes and their respective association with myocardial fibrosis and prognosis., Methods: Clusters were constructed using echocardiographic variables in a bicentric cohort of patients with MVP (n = 429, age 54 ± 15 years) and subsequently investigated for their association with myocardial fibrosis (assessed by cardiac magnetic resonance) and cardiovascular outcomes., Results: Mitral regurgitation (MR) was severe in 195 (45%) patients. Four clusters were identified: cluster 1 comprised no remodeling with mainly mild MR, cluster 2 was a transitional cluster, cluster 3 included significant left ventricular (LV) and left atrial (LA) remodeling with severe MR, and cluster 4 included remodeling with a drop in LV systolic strain. Clusters 3 and 4 featured more myocardial fibrosis than clusters 1 and 2 (P < 0.0001) and were associated with higher rates of cardiovascular events. Cluster analysis significantly improved diagnostic accuracy over conventional analysis. The decision tree identified the severity of MR along with LV systolic strain <21% and indexed LA volume >42 mL/m
2 as the 3 most relevant variables to correctly classify participants into 1 of the echocardiographic profiles., Conclusions: Clustering enabled the identification of 4 clusters with distinct echocardiographic LV and LA remodeling profiles associated with myocardial fibrosis and clinical outcomes. Our findings suggest that a simple algorithm based on only 3 key variables (severity of MR, LV systolic strain, and indexed LA volume) may help risk stratification and decision making in patients with MVP. (Genetic and Phenotypic Characteristics of Mitral Valve Prolapse, NCT03884426; Myocardial Characterization of Arrhythmogenic Mitral Valve Prolapse [MVP STAMP], NCT02879825)., Competing Interests: Funding Support and Author Disclosures This work was supported by Foundation Coeur et Recherche (Dr Le Tourneau, 2013, Paris, France) and French Ministry of Health “PHRC-I 2012” (Dr Le Tourneau, API12/N/019, Paris, France). The STAMP study (Drs Huttin and Selton-Suty) was supported by a grant from the French Ministry of Health (APJ 2015, n°: 2016-A00954-47). Dr Huttin has received honoraria form General electric and Pfizer. Dr Girerd was supported by the French National Research Agency Fighting Heart Failure (ANR-15-RHU-0004), the French PIA project Lorraine Université d’Excellence GEENAGE (ANR-15-IDEX-04-LUE) programs, and the Contrat de Plan Etat Région Lorraine and FEDER IT2MP; and has received honoraria from Lilly, Bayer, Roche Diagnostics, Novartis, AstraZeneca, Boehringer, and Vifor. Dr Le Tourneau was supported by an INSERM Translational Research Grant (2012-2016, Paris, France). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
33. Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction.
- Author
-
Patel RB, Reddy VY, Komtebedde J, Wegerich SW, Sekaric J, Swarup V, Walton A, Laurent G, Chetcuti S, Rademann M, Bergmann M, McKenzie S, Bugger H, Bruno RR, Herrmann HC, Nair A, Gupta DK, Lim S, Kapadia S, Gordon R, Vanderheyden M, Noel T, Bailey S, Gertz ZM, Trochu JN, Cutlip DE, Leon MB, Solomon SD, van Veldhuisen DJ, Auricchio A, and Shah SJ
- Subjects
- Humans, Stroke Volume, Heart Atria, Prosthesis Implantation, Prognosis, Atrial Fibrillation epidemiology, Heart Failure
- Abstract
Background: Atrial fibrillation (AF) is a common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF) and in heart failure with mildly reduced ejection fraction (HFmrEF)., Objectives: This study sought to describe AF burden and its clinical impact among individuals with HFpEF and HFmrEF who participated in a randomized clinical trial of atrial shunt therapy (REDUCE LAP-HF II [A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure]) and to evaluate the effect of atrial shunt therapy on AF burden., Methods: Study investigators characterized AF burden among patients in the REDUCE LAP-HF II trial by using ambulatory cardiac patch monitoring at baseline (median patch wear time, 6 days) and over a 12-month follow-up (median patch wear time, 125 days). The investigators determined the association of baseline AF burden with long-term clinical events and examined the effect of atrial shunt therapy on AF burden over time., Results: Among 367 patients with cardiac monitoring data at baseline and follow-up, 194 (53%) had a history of AF or atrial flutter (AFL), and median baseline AF burden was 0.012% (IQR: 0%-1.3%). After multivariable adjustment, baseline AF burden ≥0.012% was significantly associated with heart failure (HF) events (HR: 2.00; 95% CI: 1.17-3.44; P = 0.01) both with and without a history of AF or AFL (P for interaction = 0.68). Adjustment for left atrial reservoir strain attenuated the baseline AF burden-HF event association (HR: 1.71; 95% CI: 0.93-3.14; P = 0.08). Of the 367 patients, 141 (38%) had patch-detected AF during follow-up without a history of AF or AFL. Atrial shunt therapy did not change AF incidence or burden during follow-up., Conclusions: In HFpEF and HFmrEF, nearly 40% of patients have subclinical AF by 1 year. Baseline AF burden, even at low levels, is associated with HF events. Atrial shunt therapy does not affect AF incidence or burden. (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure [REDUCE LAP-HF II]; NCT03088033)., Competing Interests: Funding Support and Author Disclosures Corvia Medical, Inc has provided funding for this work. Dr Reddy has served as a consultant to and has equity in Corvia Medical; also, unrelated to this manuscript, has served as a consultant to and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Apama Medical-Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Dinova-Hangzhou Dinova EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Farapulse-Boston Scientific, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, and Valcare; unrelated to this work, has served as a consultant to Abbott, AtriAN, Biosense Webster, BioTel Heart, Biotronik, Boston Scientific, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, W.L. Gore & Associates, Impulse Dynamics, Medtronic, Philips, and Pulse Biosciences; and has equity in Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizaramed. Dr Komtebedde has been employed by Corvia Medical, Inc. Dr Walton has served as a proctor for Medtronic, Edwards Lifesciences, and Abbott; has served on advisory boards for Medtronic, Abbott, and Edwards Lifesciences; and has received grant support from Medtronic, Abbott, and Edwards Lifesciences. Dr Herrmann has received institutional research grants from Abbott, Bayer, Boston Scientific, Edwards Lifesciences, Highlife, Medtronic, Shockwave, and W.L. Gore & Associates; has received consultant fees from Medtronic, W.L. Gore & Associates, and Corazon; and has equity in Holistic Medical and Microinterventional Devices. Dr Trochu received consulting fees from Bayer, Bristol-Myers-Squibb, Abbott, AstraZeneca, and Novartis; lecture fees from Boehringer-Ingelheim and Vifor; and congress sponsoring from Corvia. Dr Auricchio has served as a consultant to Boston Scientific, Cairdac, Corvia, Microport CRM, EPD Philips, EP Solution, Radcliffe Publishers, and XSpline; has received speaker fees from Boston Scientific, Medtronic, and Microport CRM; has participated in clinical trials sponsored by Boston Scientific, Medtronic, EPD Philips, XSpline; and has intellectual properties with Boston Scientific, Biosense Webster, and Microport CRM. Dr Shah has received research grants from the National Institutes of Health (U54 HL160273, R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, GlaxoSmithKline, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Sardocor, Shifamed, Tenax, Tenaya, and United Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial.
- Author
-
von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, Da Rocha E Silva J, Näbauer M, Weber M, Tang GHL, Heitkemper M, Ying SW, Trochu JN, Kar S, Hahn RT, and Nickenig G
- Subjects
- Humans, Treatment Outcome, Prospective Studies, Cardiac Catheterization, Severity of Illness Index, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery, Heart Valve Prosthesis Implantation
- Abstract
Background: Tricuspid regurgitation (TR) is a common and progressive valve disease with significant mortality and hospitalization burden. Tricuspid transcatheter edge-to-edge repair provides a treatment option for high-risk patients with primary and secondary TR., Methods: The TRILUMINATE trial ([Trial to Evaluate Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation]; n=85) is an international, prospective, single-arm, multicenter study to investigate the safety and performance of tricuspid transcatheter edge-to-edge repair with the TriClip implant in patients with symptomatic moderate or greater TR. Echocardiographic assessment was performed at a core laboratory. Outcomes included safety and clinical effectiveness and echocardiographic assessment of TR., Results: At 2 years, TR was reduced to moderate or less in 60% of subjects, and reduction of at least 1 grade was achieved in 85.4% of subjects. TR reduction was sustained in 75% of the patients. While most metrics suggest the majority of favorable remodeling occurred within the first 30 days post-procedure, both right ventricular end diastolic diameter and tricuspid annular plane systolic excursion show signals of continued favorable remodeling through 2 years. Substantial improvements in 6-minute walking distance, New York Heart Association functional class, and Kansas City Cardiomyopathy Questionnaire score were sustained from 30 days to 2 years. Even with low rates of cardiovascular mortality (15.3%) and all-cause mortality (18.7%) noted at 2 years, all-cause hospitalization rate decreased from 1.30 events per patient-year 1 year before device implantation to 0.66 events per patient-year 2 years after the TriClip procedure, representing a reduction of 49% ( P <0.0001)., Conclusions: Tricuspid transcatheter edge-to-edge repair using the TriClip implant was found to be safe and effective, with sustained benefits at 2 years in subjects with symptomatic moderate or greater TR. Repair efficacy was durable at 2 years in 75% of the patients., Registration: URL: https://www., Clinicaltrials: gov; Unique identifier: NCT03227757., Competing Interests: Disclosures Dr von Bardeleben reports institutional research grants and speaker honorarium from Abbott Vascular and Edwards Lifesciences and nonfinancial trial support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Lifetec, and Medtronic. Dr Lurz has been a consultant to Abbott Structural Heart, Edwards Lifesciences, Medtronic, ReCor, and Occlutech. Dr Ruf has received honoraria from Abbott Vascular, Edwards Lifesciences, and TRiCares. Dr Sitges has been a consultant and has received speaker honoraria from Abbott, Edwards Lifesciences, Medtronic, and General Electric. Drs Sitges and Nickenig have received speaker honoraria and travel and grant support from Abbott. Dr Nickenig has received research funding from the Deutsche Forschungsgemeinschaft, the Federal Ministry of Education and Research, the European Union, Abbott, AGA Medical, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Sanofi, and St. Jude Medical; has received honoraria for lectures or advisory boards from Abbott, AGA Medical, AstraZeneca, Bayer, Berlin, Cardiovalve, Berlin Chemie, Biosensus, Biotronic, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Sanofi, and St. Jude Medical; and has participated in clinical trials for Abbott, AGA Medical, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, Bristol Myers Squibb, Boehringer Ingelheim, Cardiovalve, Daiichi Sankyo, Edwards Lifesciences Medtronic, Novartis, Pfizer, Sanofi, and St. Jude Medical. Dr Sorajja has received grants and personal fees from Abbott Vascular, outside the submitted work. Dr Trochu has received speaker honoraria, travel support, and grant support from Abbott and Novartis; has received honoraria for lectures or advisory boards from Amgen, Bayer, and Resmed; and has been an unpaid member of the Corvia Medical Scientific Advisory Group. Dr Hausleiter has received speaker honoraria and research support from Abbott Vascular and Edwards Lifesciences. Dr Näbauer has received speaker honoraria form Abbott. Dr Tang has received consultant fees and speaker honoraria from Abbott and Medtronic. S.-W. Ying and Dr Heitkemper have been employees of Abbott. Dr Hahn reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; she has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; and she has stock options with Navigate. The other authors report no conflicts.
- Published
- 2023
- Full Text
- View/download PDF
35. Perioperative Iron Deficiency in Patients Scheduled for Major Elective Surgeries: A French Prospective Multicenter Cross-Sectional Study.
- Author
-
Capdevila X, Lasocki S, Duchalais A, Rigal JC, Mertl P, Ghewy P, Farizon F, Lanz T, Buckert A, Belarbia S, Trochu JN, and Cacoub P
- Subjects
- Humans, Female, Aged, Cross-Sectional Studies, Prospective Studies, Hemoglobins analysis, Anemia, Iron-Deficiency diagnosis, Anemia, Iron-Deficiency epidemiology, Iron Deficiencies, Anemia epidemiology
- Abstract
Background: The management of perioperative iron deficiency is a component of the concept of patient blood management. The objective of this study was to update French data on the prevalence of iron deficiency in patients scheduled for major surgery., Methods: The CARENFER PBM study was a prospective cross-sectional study in 46 centers specialized in orthopedic, cardiac, urologic/abdominal, or gynecological surgery. The primary end point was the prevalence of iron deficiency at the time of surgery (D-1/D0) defined as serum ferritin <100 µg/L and/or transferrin saturation (TSAT) <20%., Results: A total of 1494 patients (mean age, 65.7 years; women, 49.3%) were included from July 20, 2021 to January 3, 2022. The prevalence of iron deficiency in the 1494 patients at D-1/D0 was 47.0% (95% confidence interval [CI], 44.5-49.5). At 30 days after surgery, the prevalence of iron deficiency was 45.0% (95% CI, 42.0-48.0) in the 1085 patients with available data. The percentage of patients with anemia and/or iron deficiency increased from 53.6% at D-1/D0 to 71.3% at D30 ( P < .0001), mainly due to the increase of patients with both anemia and iron deficiency (from 12.2% at D-1/D0 to 32.4% at D30; P < .0001). However, a treatment of anemia and/or iron deficiency was administered preoperatively to only 7.7% of patients and postoperatively to 21.7% (intravenous iron, 14.2%)., Conclusions: Iron deficiency was present in half of patients scheduled for major surgery. However, few treatments to correct iron deficiency were implemented preoperatively or postoperatively. There is an urgent need for action to improve these outcomes, including better patient blood management., Competing Interests: Conflicts of Interest: See Disclosures at the end of the article., (Copyright © 2023 International Anesthesia Research Society.)
- Published
- 2023
- Full Text
- View/download PDF
36. Clinical features and outcomes of patients admitted to the ICU for Cyclophosphamide-associated cardiac toxicity: a retrospective cohort.
- Author
-
Vennier A, Canet E, Guardiolle V, Reizine F, Trochu JN, Le Tourneau T, Touzeau C, Houot R, Seguin A, Reignier J, Lascarrou JB, Tadié JM, and Emarié J
- Subjects
- Humans, Retrospective Studies, Stroke Volume, Ventricular Function, Left, Intensive Care Units, Cyclophosphamide adverse effects, Shock, Cardiogenic chemically induced, Cardiotoxicity etiology
- Abstract
Purpose: To describe the management and outcome of critically-ill patients with Cyclophosphamide (CY)-associated cardiac toxicity., Methods: All patients admitted to the intensive care units (ICUs) of the Nantes and Rennes University Hospitals for a CY-associated cardiac toxicity between January 2015 and December 2020 were included., Results: Of the thirty-four patients included in the study, twenty-four (70%) underwent allogeneic hematopoietic stem cell transplantation (HSCT), four (12%) autologous HSCT, and six (18%) chemotherapy for hematological malignancies. Acute pulmonary edema (65%), cardiac arrest (9%), and cardiac arrhythmia (6%) were the most common reasons for ICU admission. Patients were admitted to the ICU 6.5 (4-12) days after the intravenous administration of a median dose of CY of 100 [60-101] mg/Kg. Echocardiographic findings showed moderate to severe left ventricular systolic dysfunction (69%) and pericardial effusion (52%). Eighteen (53%) patients ultimately developed cardiogenic shock and required vasopressors (47%) and/or inotropes (18%). Invasive mechanical ventilation and renal replacement therapy were required in twenty (59%) and five (14%) patients, respectively. Sixteen (47%) patients died of whom 12 (35.3%) died from refractory cardiogenic shock. The left ventricular ejection fraction improved over time in most survivors with a median time until full recovery of 33 (12-62) days. Two (11%) patients had a persistent left ventricular dysfunction at 6 months., Conclusion: Refractory cardiogenic shock is the primary cause of death of patients with severe CY-related cardiotoxicity. Nonetheless, the cardiac function of most survivors recovered within a month., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
37. Feasibility and accuracy of linking a heart failure registry to the national claims database using indirect identifiers.
- Author
-
Logeart D, Damy T, Doublet M, Salvat M, Tribouilloy C, Bauer F, Eicher JC, Picard F, Roul G, Trochu JN, De Groote P, Bihry N, Berthelot E, Jondeau G, Seronde MF, Roubille F, and Isnard R
- Subjects
- Humans, Stroke Volume, Feasibility Studies, Registries, Ventricular Function, Left, Heart Failure diagnosis, Heart Failure epidemiology, Heart Failure therapy
- Abstract
Background: Heart failure (HF) registries include rich data on patient inclusion characteristics, but follow-up information is often incomplete. Medicoadministrative databases may provide less clinical information than registries, e.g. on left ventricular ejection fraction (LVEF), but long-term data are exhaustive and reliable. The combination of the two types of database is therefore appealing, but the feasibility and accuracy of such linking are largely unexplored., Aims: To assess the feasibility and accuracy of linking an HF registry (FRESH; FREnch Survey on Heart Failure) with the French National Healthcare System database (SNDS)., Methods: A probabilistic algorithm was developed to link and match patient data included in the FRESH HF registry with anonymized records from the SNDS, which include: hospitalizations and diagnostic codes; all care-related reimbursements by national health system; and deaths. Consistency was assessed between deaths recorded in the registry and in the SNDS. A comparison between the two databases was carried out on several identifiable clinical characteristics (history of HF hospitalization, diabetes, atrial fibrillation, chronic bronchopneumopathy, severe renal failure and stroke) and on events during 1-year follow-up after inclusion., Results: Of 2719 patients included in the FRESH registry (1049 during decompensation; 1670 during outpatient follow-up), 1885 could be matched with a high accuracy of 94.3% for deaths. Mortality curves were superimposable, including curves according to type of HF and LVEF. The rates of missing data in the FRESH registry were 2.3-8.4% for clinical characteristics and 17.5% for hospitalizations during follow-up. The discrepancy rate for clinical characteristics was 3-13%. Hospitalization rates were significantly higher in the SNDS than in the registry cohort., Conclusions: The anonymous matching of an HF research cohort with a national health database is feasible, with a significant proportion of patients being accurately matched, and facilitates combination of clinical data and a reduced rate of losses to follow-up., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
38. Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study.
- Author
-
Peyrin-Biroulet L, Bouguen G, Laharie D, Pellet G, Savoye G, Gilletta C, Michiels C, Buisson A, Fumery M, Trochu JN, and Cacoub P
- Subjects
- Adult, Humans, Female, Middle Aged, Male, Cross-Sectional Studies, Prospective Studies, Iron, Inflammation complications, Iron Deficiencies, Anemia, Iron-Deficiency diagnosis, Anemia, Iron-Deficiency epidemiology, Colitis, Ulcerative complications, Colitis, Ulcerative diagnosis, Colitis, Ulcerative drug therapy, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases epidemiology, Anemia etiology
- Abstract
Background: Iron deficiency (ID) is a frequent condition in patients with inflammatory bowel disease (IBD)., Aim: Our aim was to investigate the prevalence of ID in patients with IBD., Methods: This was a prospective multicenter cross-sectional study conducted in 21 gastroenterology departments in France between January and March 2020. All adult patients with confirmed IBD who were admitted to the hospital were eligible for inclusion. ID was defined as ferritinemia ≤ 100 μg/L in patients with signs of inflammation (C-reactive protein (CRP) ≥ 5 mg/L) or ferritinemia < 30 μg/L in the absence of inflammation., Results: In total, 1036 IBD (685 Crohn's disease and 351 ulcerative colitis) patients (52.1% women) with a mean age of 41.8 ± 15.5 years were recruited. Approximately half of the patients (504, 51.1%) were in disease remission at the time of enrollment. Systematic monitoring of iron status was performed in 12/21 (57%) participating centers, including measurements of ferritin (12/12, 100%), hemoglobin (11/12, 92%), transferrin saturation (TSAT) (6/12, 50.0%), and serum iron (5/12, 42%). About one-fifth of the patients had been treated with intravenous iron (218, 21.0%), whereas only a small percentage received oral iron (36, 3.5%). ID occurred in 97 patients (23.7% CI 95% 19.8-28.1). Patients with moderate/severe IBD activity (OR: 3.66; CI 95% 24.4-61.2; p = 0.007) or concomitant anemia (OR: 3.66; CI 95% 1.97-6.78; p < 0.001) had an increased likelihood of having ID., Conclusion: Patients with moderate/severe IBD activity or concomitant anemia are at increased risk of ID. Early detection and management of ID in patients with IBD is recommended., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
39. Renal function decline and heart failure hospitalisation in patients with type 2 diabetes: Dynamic predictions from the prospective SURDIAGENE cohort.
- Author
-
Dantan E, Pailler M, Ragot S, Gand E, Trochu JN, Cariou B, Saulnier PJ, and Hadjadj S
- Subjects
- Humans, Prospective Studies, Glomerular Filtration Rate, Kidney physiology, Risk Factors, Diabetes Mellitus, Type 2 complications, Heart Failure, Renal Insufficiency, Chronic complications
- Abstract
Aims: For type 2 diabetes persons, we assessed the association between renal function decline and heart failure hospitalisation (HFH) and validated dynamic HFH predictions (DynHFH) based on repeated estimated Glomerular Filtration Rate (eGFR) values., Methods: We studied 1413 patients from the SURDIAGENE cohort. From a joint model for longitudinal CKD-EPI measures and HFH risk, we calculated the probability of being HFH-free in the next five years., Results: The mean eGFR decline was estimated at 1.48 ml/min/1.73 m
2 per year (95 % CI from 1.23 to 1.74). We observed that eGFR decline was significantly associated with the HFH risk (adj HR = 1.15 for an increase in yearly decline of 1 ml/min/1.73 m2 , 95 % CI from 1.03 to 1.26) independently of 7 baseline variables (from clinical, biological and ECG domains). Discrimination was good along the prediction times: AUC at 0.87 (95 %CI from 0.84 to 0.91) at patient inclusion and 0.77 (95 %CI from 0.67 to 0.87) at seven years' follow-up., Conclusions: Renal function decline was significantly associated with the HFH risk. In the era of computer-assisted medical decisions, the DynHFH, a tool that dynamically predicts HFH in type 2 diabetes persons (https://shiny.idbc.fr/DynHFH), might be helpful for precision medicine and the implementation of stratified medical decision-making., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
40. Multicentric randomized evaluation of a tricuspid valve percutaneous repair system (clip for the tricuspid valve) in the treatment of severe secondary tricuspid regurgitation Tri.Fr Design paper.
- Author
-
Donal E, Leurent G, Ganivet A, Lurz P, Coisne A, De Groote P, Lafitte S, Leroux L, Karam N, Biere L, Rouleau F, Sportouch C, Dreyfus J, Nejjari M, Josselin JM, Anselmi A, Galli E, Bajeux E, Guerin P, Obadia JF, Trochu JN, and Oger E
- Subjects
- Humans, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Cardiac Catheterization methods, Treatment Outcome, Surgical Instruments, Severity of Illness Index, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery, Heart Valve Prosthesis Implantation methods
- Abstract
Aims: Tricuspid regurgitation (TR) is associated with significant morbidity and mortality. Its independent prognostic role has been repeatedly demonstrated. However, this valvular heart condition is largely undertreated because of the increased risk of surgical repair. Recently, transcatheter techniques for the treatment of TR have emerged, but their implications for the clinical endpoints are still unknown., Methods and Results: The Tri.fr trial will be a multicentre, controlled, randomized (1:1 ratio), superior, open-label, and parallel-group study conducted in 300 patients with severe secondary TR that is considered non-surgical by heart teams. Inclusion will be possible only after core laboratory review of transthoracic and transoesophageal echocardiography and after validation by the clinical eligibility committee. A description of the mechanisms of the TR will be conducted by the core laboratory. Atrial or ventricular impacts on the severity of the secondary TR will be taken into account for the randomization. The patients will be followed for 12-month, and the primary outcome will be the Packer composite clinical endpoint [combining New York Heart Association class, patient global assessment (PGA), and major cardiovascular events]. It will test the hypothesis that a tricuspid valve percutaneous repair strategy using a clip dedicated to the tricuspid valve is superior to best guideline-directed medical therapy in symptomatic patients with severe secondary TR., Conclusion: Tri.fr will be the first randomized, academic, multicentre study testing the value of percutaneous correction in patients with severe secondary TR., Competing Interests: Conflict of interest: Abbott is providing the implanted device, but the study is academic, independent and financed by the French Minister for Health (PHRC-N)., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
41. Impact of procedural success on clinical outcome after MitraClip: Results from the MITRA-FR trial.
- Author
-
Messika-Zeitoun D, Attias D, Piriou N, Iung B, Armoiry X, Trochu JN, Donal E, Habib G, Cormier B, Guerin P, Lefèvre T, Maucort-Boulch D, Boutitie F, Vahanian A, Riche B, and Obadia JF
- Subjects
- Humans, Stroke Volume, Ventricular Function, Left, Treatment Outcome, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency surgery, Mitral Valve Insufficiency etiology, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation methods, Heart Failure diagnosis, Heart Failure therapy, Heart Failure complications
- Abstract
Background: Differences in procedural success rates have been proposed to explain the divergent results between the MITRA-FR trial (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation) and the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation)., Aim: To examine whether MITRA-FR patients who had successful clip implantation achieved a better outcome than the control group., Methods: Based on the per protocol population of MITRA-FR, we compared the outcome in 71 patients in whom optimal clip implantation was achieved (group 1: mitral regurgitation grade ≤ 1 + at discharge) with that in 23 patients with non-optimal clip implantation (group 2: mitral regurgitation grade ≥ 2 + at discharge) and that in 137 patients in the control group (group 3). The primary endpoint was all-cause death or unplanned hospitalization for heart failure at 24 months., Results: Event-free survival was not different across the groups (42±6% in group 1, 30±10% in group 2 and 31±4% in group 3; log-rank P=0.32). In multivariable analyses, after adjustment for age, sex, rhythm, aetiology, left ventricular ejection fraction and mitral regurgitation severity, group was not associated with variations in outcome: using Group 3 as reference, hazard ratio 0.86, 95% confidence interval 0.58-1.27 (P=0.43) in group 1; and hazard ratio 0.98 95% confidence interval 0.54-1.76 (P=0.94) in group 2., Conclusions: The clinical outcome of patients in whom optimal procedural result was achieved at discharge was not different compared with the control group. Our results do not support the hypothesis that the differences in rates of residual mitral regurgitation at discharge between MITRA-FR and COAPT explain the divergent results between the two trials., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
42. Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.
- Author
-
Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoc'h K, Andrieu V, Lasocki S, Puy H, and Trochu JN
- Subjects
- Biomarkers, Chronic Disease, Cytokines, Ferritins, Hepcidins therapeutic use, Humans, Iron therapeutic use, Quality of Life, Transferrins therapeutic use, Anemia, Anemia, Iron-Deficiency diagnosis, Anemia, Iron-Deficiency etiology, Iron Deficiencies
- Abstract
Iron deficiency is frequent in patients with chronic inflammatory conditions (e.g., chronic heart failure, chronic kidney disease, cancers, and bowel inflammatory diseases). Indeed, high concentrations of inflammatory cytokines increase hepcidin concentrations that lead to the sequestration of iron in cells of the reticuloendothelial system (functional iron deficiency). Iron parameters are often assessed only in the context of anemia, but iron deficiency, even without anemia, is present in about half of patients with inflammatory conditions. Iron deficiency worsens underlying chronic diseases and is an independent factor of morbidity and mortality. In daily practice, the most effective biomarkers of iron status are serum ferritin, which reflects iron storage, and transferrin saturation, which reflects the transport of iron. Serum ferritin is increased in an inflammatory context, and there is still no consensus on the threshold to be used in chronic inflammatory conditions. Nevertheless, recent recommendations of international guidelines agreed to define iron deficiency by serum ferritin <100 µg/L and/or transferrin saturation <20%. Iron parameters remain, however, insufficiently assessed in patients with chronic inflammatory conditions. Indeed, clinical symptoms of iron deficiency, such as fatigue, are not specific and often confused with those of the primary disease. Iron repletion, preferably by the intravenous route to bypass tissue sequestration, improves clinical signs and quality of life. Because of the negative impact of iron deficiency on chronic inflammatory diseases and the efficacy of intravenous iron repletion, screening of iron parameters should be part of the routine examination of all patients with chronic inflammatory diseases., (© 2022 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.)
- Published
- 2022
- Full Text
- View/download PDF
43. Acute Myocarditis Associated With Desmosomal Gene Variants.
- Author
-
Ammirati E, Raimondi F, Piriou N, Sardo Infirri L, Mohiddin SA, Mazzanti A, Shenoy C, Cavallari UA, Imazio M, Aquaro GD, Olivotto I, Pedrotti P, Sekhri N, Van de Heyning CM, Broeckx G, Peretto G, Guttmann O, Dellegrottaglie S, Scatteia A, Gentile P, Merlo M, Goldberg RI, Reyentovich A, Sciamanna C, Klaassen S, Poller W, Trankle CR, Abbate A, Keren A, Horowitz-Cederboim S, Cadrin-Tourigny J, Tadros R, Annoni GA, Bonoldi E, Toquet C, Marteau L, Probst V, Trochu JN, Kissopoulou A, Grosu A, Kukavica D, Trancuccio A, Gil C, Tini G, Pedrazzini M, Torchio M, Sinagra G, Gimeno JR, Bernasconi D, Valsecchi MG, Klingel K, Adler ED, Camici PG, and Cooper LT Jr
- Subjects
- Gadolinium, Humans, Retrospective Studies, Stroke Volume, Troponin, Ventricular Function, Left, Young Adult, Heart Failure, Myocarditis genetics
- Abstract
Background: The risk of adverse cardiovascular events in patients with acute myocarditis (AM) and desmosomal gene variants (DGV) remains unknown., Objectives: The purpose of this study was to ascertain the risk of death, ventricular arrhythmias, recurrent myocarditis, and heart failure (main endpoint) in patients with AM and pathogenic or likely pathogenetic DGV., Methods: In a retrospective international study from 23 hospitals, 97 patients were included: 36 with AM and DGV (DGV[+]), 25 with AM and negative gene testing (DGV[-]), and 36 with AM without genetics testing. All patients had troponin elevation plus findings consistent with AM on histology or at cardiac magnetic resonance (CMR). In 86 patients, CMR changes in function and structure were re-assessed at follow-up., Results: In the DGV(+) AM group (88.9% DSP variants), median age was 24 years, 91.7% presented with chest pain, and median left ventricular ejection fraction (LVEF) was 56% on CMR (P = NS vs the other 2 groups). Kaplan-Meier curves demonstrated a higher risk of the main endpoint in DGV(+) AM compared with DGV(-) and without genetics testing patients (62.3% vs 17.5% vs 5.3% at 5 years, respectively; P < 0.0001), driven by myocarditis recurrence and ventricular arrhythmias. At follow-up CMR, a higher number of late gadolinium enhanced segments was found in DGV(+) AM., Conclusions: Patients with AM and evidence of DGV have a higher incidence of adverse cardiovascular events compared with patients with AM without DGV. Further prospective studies are needed to ascertain if genetic testing might improve risk stratification of patients with AM who are considered at low risk., Competing Interests: Funding Support and Author Disclosures Dr Ammirati has received a grant from the Italian Ministry of Health (GR-2019-12368506) and is a consultant for Kiniksa and Cytokinetics. Dr Adler is a consultant for Abbott, Abiomed, AstraZeneca, Endotronix, Ionis, Medtronic, and Novartis; is on the board of directors of Genstem Therapeutics; and is a shareholder of Rocket Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
44. Delayed hospitalisation for heart failure after transcatheter repair or medical treatment for secondary mitral regurgitation: a landmark analysis of the MITRA-FR trial.
- Author
-
Leurent G, Auffret V, Donal E, Corbineau H, Grinberg D, Bonnet G, Leroux PY, Guérin P, Wautot F, Lefèvre T, Messika-Zeitoun D, Iung B, Armoiry X, Trochu JN, Boutitie F, and Obadia JF
- Subjects
- Cardiac Catheterization adverse effects, Hospitalization, Humans, Treatment Outcome, Heart Failure complications, Heart Failure therapy, Heart Valve Prosthesis Implantation adverse effects, Mitral Valve Insufficiency complications
- Abstract
Background: In the MITRA-FR trial, transcatheter mitral valve repair (TMVR) was not associated with a 2-year clinical benefit in patients with secondary mitral regurgitation (SMR)., Aims: This landmark analysis aimed at investigating a potential reduction of the hospitalisation rate for heart failure (HF) between 12 and 24 months after inclusion in the MITRA-FR trial in patients randomised to the intervention group (TMVR with the MitraClip device), as compared with patients randomised to the control group (guideline-directed medical therapy [GDMT])., Methods: The MITRA-FR trial randomised 307 patients with SMR for TMVR on top of GDMT (TMVR group; n=152) or for GDMT alone (control group; n=155). We conducted a 12-month landmark analysis in surviving patients who were not hospitalised for HF within the first 12 months of follow-up. The primary endpoint was the 1-year cumulative number of HF hospitalisations., Results: A total of 140 patients (TMVR group: 67; GDMT group: 73) were selected for this landmark analysis with similar characteristics at inclusion in the trial. The primary endpoint was 28 events per 100 patient-years in the TMVR group, as compared with 60 events per 100 patient-years in the GDMT group (hazard ratio [HR] 0.46, 95% confidence interval [CI]: 0.20-1.02; p=0.057)., Conclusions: In this landmark analysis of the MITRA-FR trial, the cumulative rate of HF hospitalisation between 12 and 24 months among patients treated with TMVR on top of GDMT was approximately half as many as those of patients treated with GDMT alone, a difference which did not reach statistical significance in the setting of a low number of events.
- Published
- 2022
- Full Text
- View/download PDF
45. 18F-Fluorodeoxyglucose Positron Emission Tomography for the Detection of Myocardial Inflammation in Arrhythmogenic Left Ventricular Cardiomyopathy.
- Author
-
Tessier R, Marteau L, Vivien M, Guyomarch B, Thollet A, Fellah I, Jamet B, Sébille JC, Eugene T, Serfaty JM, Probst V, Trochu JN, Toquet C, Warin-Fresse K, and Piriou N
- Subjects
- Fluorodeoxyglucose F18, Humans, Inflammation diagnostic imaging, Positron Emission Tomography Computed Tomography methods, Positron-Emission Tomography methods, Radiopharmaceuticals, Cardiomyopathies diagnostic imaging, Cardiomyopathies etiology, Myocarditis diagnostic imaging
- Published
- 2022
- Full Text
- View/download PDF
46. Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort.
- Author
-
Wargny M, Croyal M, Ragot S, Gand E, Jacobi D, Trochu JN, Prieur X, Le May C, Goronflot T, Cariou B, Saulnier PJ, and Hadjadj S
- Subjects
- Aged, Betaine, Biomarkers, Carnitine, Choline, Cohort Studies, Cysteine, Female, Homocysteine, Hospitalization, Humans, Male, Methionine, Middle Aged, Prospective Studies, Risk Factors, Diabetes Mellitus, Type 2 diagnosis, Heart Failure diagnosis
- Abstract
Background: Heart failure (HF) is a growing complication and one of the leading causes of mortality in people living with type 2 diabetes (T2D). Among the possible causes, the excess of red meat and the insufficiency of vegetables consumption are suspected. Such an alimentation is associated with nutritional biomarkers, including trimethylamine N-oxide (TMAO) and its precursors. Here, we aimed to study these biomarkers as potential prognostic factors for HF in patients with T2D., Methods: We used the SURDIAGENE (SURvival DIAbetes and GENEtics) study, a large, prospective, monocentric cohort study including 1468 patients with T2D between 2001 and 2012. TMAO and its precursors (trimethylamine [TMA], betaine, choline, and carnitine) as well as thio-amino-acids (cysteine, homocysteine and methionine) were measured by liquid chromatography-tandem mass spectrometry. The main outcome was HF requiring Hospitalization (HFrH) defined as the first occurrence of acute HF leading to hospitalization and/or death, established by an adjudication committee, based on hospital records until 31st December 2015. The secondary outcomes were the composite event HFrH and/or cardiovascular death and all-cause death. The association between the biomarkers and the outcomes was studied using cause-specific hazard-models, adjusted for age, sex, history of coronary artery disease, NT-proBNP, CKD-EPI-derived eGFR and the urine albumin/creatinine ratio. Hazard-ratios (HR) are expressed for one standard deviation., Results: The data of interest were available for 1349/1468 of SURDIAGENE participants (91.9%), including 569 (42.2%) women, with a mean age of 64.3 ± 10.7 years and a median follow-up of 7.3 years [25th-75th percentile, 4.7-10.8]. HFrH was reported in 209 patients (15.5%), HFrH and/or cardiovascular death in 341 (25.3%) and all-cause death in 447 (33.1%). In unadjusted hazard-models, carnitine (HR = 1.20, 95% CI [1.05; 1.37]), betaine (HR = 1.34, [1.20; 1.50]), choline (HR = 1.35, [1.20; 1.52]), TMAO (HR = 1.32, [1.16; 1.50]), cysteine (HR = 1.38, [1.21; 1.58]) and homocysteine (HR = 1.28, [1.17; 1.39]) were associated with HFrH, but not TMA and methionine. In the fully adjusted models, none of these associations was significant, neither for HFrH nor for HFrH and/or CV death, when homocysteine only was positively associated with all-cause death (HR = 1.16, [1.06; 1.27])., Conclusions: TMAO and its precursors do not appear to be substantial prognosis factors for HFrH, beyond usual cardiac- and kidney-related risk factors, whereas homocysteine is an independent risk factor for all-cause death in patients with T2D., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
47. [Prevalence of iron deficiency in patients with non-dialysis chronic kidney disease: The CARENFER national, multicentre, observational study].
- Author
-
Choukroun G, Kazes I, Dantal J, Vabret E, Couzi L, Le Meur Y, Trochu JN, and Cacoub P
- Subjects
- Adult, Ferritins, Humans, Iron, Prevalence, Transferrins, Anemia, Iron-Deficiency diagnosis, Anemia, Iron-Deficiency epidemiology, Anemia, Iron-Deficiency etiology, Iron Deficiencies, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic epidemiology
- Abstract
Introduction: Iron deficiency is common and associated with worse outcomes in patients with non-dialysis chronic kidney disease. We performed a national, multicentre, observational and transversal study to assess the prevalence of iron deficiency as well as current iron deficiency screening practices in this population., Patients and Methods: A total of 25 nephrology centres in France participated in the study. All adult non-dialysis chronic kidney disease patients who met the inclusion (GFR>15mL/min/1.73m
2 ) and exclusion criteria and provided consent were systematically recruited over a 4-week inclusion period. Investigators were asked to perform a blood test (hemoglobin concentration, serum iron, serum ferritin and transferrin saturation) and to complete a questionnaire about their iron status monitoring practices. The primary objective was to assess the prevalence of iron deficiency (serum ferritin<100μg/L and/or transferrin saturation<20%). Secondary objectives were to evaluate the prevalence of absolute iron deficiency (serum ferritin<100μg/L and transferrin saturation<20%) and functional iron deficiency (serum ferritin≥100μg/L and transferrin saturation<20%), the prevalence of iron deficiency according to haemoglobin concentration and chronic kidney disease stage, the proportion of centres that perform routine evaluation of iron status and the number of patients receiving iron supplementation., Results: A total of 1211 patients with non-dialysis chronic kidney disease were included in the analysis. The overall prevalence of iron deficiency was 47.1%. The rates of absolute iron deficiency and functional iron deficiency and anaemia were 13.4% and 17.1%, respectively. Among the 25 participating centres, 12 reported routine assessment of iron status in non-dialysis chronic kidney disease patients., Conclusion: In this observational study, a high prevalence of iron deficiency was observed among non-dialysis chronic kidney disease patients. Less than half of participating centres reported routine assessment of iron status., (Copyright © 2022. Published by Elsevier Masson SAS.)- Published
- 2022
- Full Text
- View/download PDF
48. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
- Author
-
Borlaug BA, Blair J, Bergmann MW, Bugger H, Burkhoff D, Bruch L, Celermajer DS, Claggett B, Cleland JGF, Cutlip DE, Dauber I, Eicher JC, Gao Q, Gorter TM, Gustafsson F, Hayward C, van der Heyden J, Hasenfuß G, Hummel SL, Kaye DM, Komtebedde J, Massaro JM, Mazurek JA, McKenzie S, Mehta SR, Petrie MC, Post MC, Nair A, Rieth A, Silvestry FE, Solomon SD, Trochu JN, Van Veldhuisen DJ, Westenfeld R, Leon MB, and Shah SJ
- Subjects
- Female, Humans, Male, Pulmonary Circulation, Stroke Volume, Treatment Outcome, Cardiac Catheterization instrumentation, Heart Atria surgery, Heart Failure surgery, Vascular Diseases complications
- Abstract
Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit., Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome-a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status-was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization., Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P =0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P =0.038). Patients with larger right atrial volumes and men had worse outcomes with the device and both groups were more likely to have pacemakers, heart failure with mildly reduced ejection fraction, and increased left atrial volume. For patients without latent PVD or pacemaker (n=313; 50% of randomized patients), shunt treatment resulted in more robust signal of clinical benefit (win ratio, 1.51 [95% CI, 1.14, 2.00]; P =0.004)., Conclusions: In patients with heart failure with preserved or mildly reduced ejection fraction, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.
- Published
- 2022
- Full Text
- View/download PDF
49. Iron deficiency in heart failure patients: the French CARENFER prospective study.
- Author
-
Cohen-Solal A, Philip JL, Picard F, Delarche N, Taldir G, Gzara H, Korichi A, Trochu JN, and Cacoub P
- Subjects
- Aged, Cross-Sectional Studies, Humans, Prospective Studies, Quality of Life, Stroke Volume, Ventricular Function, Left, Heart Failure complications, Heart Failure epidemiology, Iron Deficiencies
- Abstract
Aims: Iron deficiency (ID) is reported as one of the main co-morbidities in patients with chronic heart failure (CHF), which then influences quality of life and prognosis. The CARENFER study aimed to assess the prevalence of ID in a large panel of heart failure (HF) patients at different stages of the disease., Methods and Results: This prospective cross-sectional nationwide study was conducted in 48 medical units in France in 2019. Serum ferritin concentration and transferrin saturation (TSAT) index were determined in all eligible patients with a diagnosis of HF. ID diagnosis was based on the European Society of Cardiology (ESC) 2016 guidelines. Patients were classified as having either a decompensated HF or a CHF. Left ventricular ejection fraction (LVEF) was categorized as preserved (≥50%), mildly reduced (40-49%), or reduced (<40%). ID diagnosis was determined in 1661 patients, of whom 1475 could be classified as having a decompensated HF or a CHF. Patients' median age was 78 years. Decompensated HF represented 60.1% of cases. The overall prevalence of ID was 49.6% (47.1-52.1). In CHF and decompensated HF patients, respectively, ID prevalence was 39.0% (35.1-43.1) and 58.1% (54.7-61.4), P < 0.001; TSAT < 20% was respectively reported in 34.7% and 70.0% of patients (P < 0.001). Patients with preserved LVEF were more likely to have an ID (57.5%) compared with patients with mildly reduced (47.4%) or reduced LVEF (44.3%) (P < 0.001)., Conclusions: Iron deficiency was highly prevalent in patients with decompensated HF or CHF with preserved LVEF. ID prevalence defined by TSAT was higher than by the ESC criteria in decompensated HF patients, questioning the importance of ID definition to assess its prevalence., (© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
50. Amylose cardiaque dite sénile : diagnostic et nouvelles perspectives thérapeutiques.
- Author
-
Berrut G, Piriou N, Boureau AS, Hanon O, and Trochu JN
- Subjects
- Amylose, Humans, Amyloidosis, Prealbumin
- Abstract
Résumé L'amylose cardiaque dite sénile, également dénommée « sauvage », était considérée comme une maladie rare. Actuellement, grâce à des moyens diagnostiques non invasifs et à partir d'études autopsiques, nous estimons la prévalence à environ 10 à 20 % des sujets de plus de 80 ans. De même, l'amylose était un diagnostic sans conséquence thérapeutique, mis à part le traitement de l'insuffisance cardiaque et des troubles de conduction. De nouveaux traitements permettent de stabiliser le tétramère de transthyrétine et de diminuer la production d'oligomères, sources des dépôts d'amylose, en cas de formes héréditaires et sauvage d'amylose à transthyrétine. Deux médicaments bloquant la production de transthyrétine (anti-sens et oligonucléotides) sont également en phase d'essais cliniques dans les amyloses cardiaques. Ainsi, le diagnostic et la prise en charge de l'amylose cardiaque deviennent des démarches diagnostiques de pratique clinique et doivent être connus des cardiologues, mais également des gériatres qui permettront une prise en charge précoce et donc plus efficace. Abstract So-called senile cardiac amyloidosis was considered rare. Nowadays, thanks to non-invasive diagnostic means and autopsy studies, we estimate the prevalence to be about 20% of subjects over 75 years of age. Similarly, amyloidosis was a diagnosis with no therapeutic consequences, apart from the treatment of heart failure and conduction disorders. New treatments make it possible to stabilise the transthyretin tetramer and to reduce the production of oligomers that are the source of amyloid deposits, by acting in a non-genetic way and therefore adapted to the "wild" transthyretin forms of so-called senile cardiac amyloidosis. Thus, the diagnosis and management of cardiac amyloidosis are becoming diagnostic procedures in clinical practice and must be known by cardiologists, but also by geriatricians, who will allow early and therefore more effective management.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.